Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 709. Отображено 100.
02-05-2013 дата публикации

HEMOSTATIC COMPOSITIONS

Номер: US20130108671A1
Автор: Dwyer Joseph F., McCoy Jill, Yang Ziping
Принадлежит:

The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer. 1. A hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis , wherein the composition is present in paste form containing 15.0 to 19.5% (w/w) crosslinked gelatin , and wherein the composition comprises an extrusion enhancer.2. The hemostatic composition according to claim 1 , wherein the extrusion enhancer is albumin in an amount of between 0.5 to 5.0% (w/w).3. The hemostatic composition according to claim 1 , wherein the crosslinked gelatin is glutaraldehyde-crosslinked gelatin or genipin-crosslinked gelatin.4. The hemostatic composition according to claim 1 , wherein the crosslinked gelatin is type B gelatin.5. The hemostatic composition according to claim 1 , wherein the crosslinked gelatin is present as granular material.6. The hemostatic composition according to claim 1 , wherein the crosslinked gelatin has a particle size of 100 to 1000 μm.7. The hemostatic composition according to claim 1 , wherein the composition contains thrombin.8. The hemostatic composition to for use in the treatment of an injury selected from the group consisting of a wound claim 1 , a hemorrhage claim 1 , a damaged tissue claim 1 , a bleeding tissue claim 1 , and a bone defect.9. A method of treating an injury selected from the group consisting of a wound claim 1 , a hemorrhage claim 1 , a damaged tissue claim 1 , and a bleeding tissue claim 1 , comprising administering a hemostatic composition according to to the injury.10. A kit for making a flowable paste of crosslinked ...

Подробнее
Номер записи: 1
20-06-2013 дата публикации

MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS

Номер: US20130156849A1
Автор: AFEYAN Noubar B., de Fougerolles Antonin, Elbashir Sayda M., Schrum Jason P., Valencia Pedro, Wood Kristy M.
Принадлежит: Moderna Therapeutics

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity. 1. A method of producing a polypeptide of interest in a mammalian cell or tissue , the method comprising , contacting said mammalian cell or tissue with a formulation comprising a modified mRNA encoding the polypeptide of interest , wherein the formulation is selected from the group consisting of nanoparticles , poly(lactic-co-glycolic acid) (PLGA) microspheres , lipidoid , lipoplex , liposome , polymers , carbohydrates (including simple sugars) , cationic lipids , fibrin gel , fibrin hydrogel , fibrin glue , fibrin sealant , fibrinogen , thrombin , rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.2. The method of claim 1 , wherein the modified mRNA comprises a purified IVT transcript.3. The method of claim 1 , wherein the formulation comprising the modified mRNA is a nanoparticle and wherein said nanoparticle comprises at least one lipid.4. The method of claim 3 , wherein the lipid is selected from the group consisting of DLin-DMA claim 3 , DLin-K-DMA claim 3 , 98N12-5 claim 3 , C12-200 claim 3 , DLin-MC3-DMA claim 3 , DLin-KC2-DMA claim 3 , DODMA claim 3 , PLGA claim 3 , PEG claim 3 , PEG-DMG and PEGylated lipids.5. The method of claim 3 , wherein the lipid is cationic lipid.6. The method of claim 5 , wherein the cationic lipid is selected from the group consisting of DLin-DMA claim 5 , DLin-K-DMA claim 5 , DLin-MC3-DMA claim 5 , DLin-KC2-DMA and DODMA.7. The method of claim 3 , wherein the lipid to modified mRNA weight ratio is between 10:1 claim 3 , and 30:1.8. ...

Подробнее
Номер записи: 2
24-10-2013 дата публикации

FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS

Номер: US20130280236A1
Автор: Hansson Kenny M., Lõvgren Ann Eva Monica
Принадлежит: MedImmune Limited

The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s). 1. A method of normalizing impaired haemostasis in a mammal in need thereof comprising administering a clotting factor treatment selected from the group consisting of (1) FII , (2) a combination of FII , FVIIa , and FX , (3) fibrinogen and a combination of FII , FVIIa , and FX , and (4) fibrinogen and FII.2. A method of increasing maximum clot firmness (MCF) in a mammal having impaired haemostasis , comprising administering a clotting factor treatment selected from the group consisting of (1) FII , (2) a combination of FII , FVIIa , and FX , (3) fibrinogen and a combination of FII , FVIIa , and FX , and (4) fibrinogen and FII.3. A method of reducing coagulation time (CT) in a mammal having impaired haemostasis , comprising administering a clotting factor treatment selected from the group consisting of (1) FII , (2) a combination of FII , FVIIa , and FX , (3) fibrinogen and a combination of FII , FVIIa , and FX , and (4) fibrinogen and FII.4. A method of improving thrombin generation in a mammal having impaired haemostasis , comprising administering a clotting factor treatment selected from the group consisting of (1) FII , (2) a combination of FII , FVIIa , and FX , (3) fibrinogen and a combination of FII , FVIIa , and FX , and (4) fibrinogen and FII.5. The method of claim 1 , wherein said impaired haemostasis is associated with a bleeding disorder claim 1 , hemorrhage claim 1 , massive blood loss or a traumatic bleeding event.6. The method of claim 5 , wherein said massive blood loss is associated with coagulopathy.7. (canceled)8. The method of claim 5 , wherein said hemorrhage or traumatic ...

Подробнее
Номер записи: 3
05-12-2013 дата публикации

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

Номер: US20130325061A1
Автор: Ingenito Edward P., Krom James A., Schwarz Alexander, Tsai Larry W.
Принадлежит: Aeris Therapeutics, LLC

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 149-. (canceled)50. A method of attaching a first tissue to a second tissue of a patient in need thereof , comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby attaching said first tissue to said second tissue.5155-. (canceled)56. The method of claim 50 , wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; and said first nucleophilic groups are selected from the group consisting of alcohols claim 50 , amines ...

Подробнее
Номер записи: 4
23-01-2014 дата публикации

HEMOSTATIC COMPOSITIONS

Номер: US20140023714A1
Автор: Forest Patricia, Gagnieu Christian, Picot Sylvain
Принадлежит: BIOM'UP

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device. 117.-. (canceled)18. A hemostatic composition in powder form comprising:collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, andat least one monosaccharide.19. The composition of claim 18 , wherein said composition comprises a collagen content ranging from 80% to 90% by weight relative to the total weight of the composition.20. The composition of claim 18 , wherein said composition comprises a monosaccharide content ranging from 1% to 12.5% by weight relative to the total weight of the composition.21. The composition of claim 18 , wherein said composition comprises a collagen/monosaccharide weight ratio ranging from 10 to 50 claim 18 , and preferably of 19.22. The composition of claim 18 , wherein the collagen comprises a content of fibrous collagen and/or fibrillar collagen ranging from 85% to 95% by weight relative to the total weight of the collagen.23. The composition of claim 18 , wherein said composition further comprises a glycosaminoglycan content ranging from 2% to 25% by weight relative to the total weight of the composition.24. The composition of claim 18 , wherein said composition further comprises a collagen/total carbohydrate compounds weight ratio ranging from 2 to 40 claim 18 , wherein the weight of the total carbohydrate compounds is the sum of the weight of the monosaccharide(s) and the weight of the glycosaminoglycan(s).25. The ...

Подробнее
Номер записи: 5
06-03-2014 дата публикации

Blood Plasma Based Hydrogels for Tissue Regeneration and Wound Healing Applications

Номер: US20140065106A1
Автор: Christy Robert, Natesan Shanmugasundaram, Suggs Laura, Zamora David
Принадлежит: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications. 1. A composition comprising plasma in which at least a portion of the fibrinogen present in the plasma is co-polymerized with polyethylene glycol.2. The composition of wherein the plasma is from an allogenic source.3. The composition of wherein the plasma is platelet free plasma.4. The composition of wherein the plasma is platelet rich plasma.5. The composition of further comprising one or more components chosen from growth factors claim 1 , extracellular matrix proteins claim 1 , therapeutic drugs claim 1 , and antibiotics.6. The composition of further comprising therapeutic cells.7. The composition of further comprising adipose derived stem cells.8. The composition of further comprising a fibrinogen-converting agent.9. The composition of further comprising a fibrinolytic inhibitor.10. The composition of wherein the composition is a hydrogel.11. The composition of wherein the polyethylene glycol is bifunctional.12. The composition of wherein the polyethylene glycol is SG-PEG-SG.13. A method comprising providing a PEGylated plasma and initiating crosslinking of the PEGylated plasma to form a hydrogel.14. The method of claim 13 , wherein the PEGylated plasma is formed by copolymerizing polyethylene glycol to at least a portion of fibrinogen present in a plasma.15. The method of claim 13 , wherein the initiating crosslinking of the PEGylated plasma comprises introducing a fibrinogen-converting agent to the PEGylated plasma.16. The method of wherein the PEGylated plasma is formed from platelet free plasma.17. The method of wherein the PEGylated plasma is formed from platelet rich plasma.18. The method of wherein the plasma is from an allogenic source.19. A method comprising ...

Подробнее
Номер записи: 6
13-03-2014 дата публикации

ROLLED COLLAGEN CARRIER

Номер: US20140072612A1
Автор: Bertelsen Poul, Blanka Ingrid, Braender Henrik, Larsen Henrik Neuschaefer, Pedersen Pernille Dybendal, Schoenhofer Wolfgang
Принадлежит: TAKEDA PHARMA A/S

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery. 160.-. (canceled)62. A process according to claim 61 , wherein the coiling is performed by gripping the collagen carrier using at least one pair of tweezers or pincers.63. A process according to claim 61 , wherein at least the coating layer of said collagen carrier is humidified claim 61 , and wherein the coating layer has been humidified using a solvent.64. A process according to claim 63 , wherein the solvent comprises ethanol.65. A process according to claim 61 , further comprising compressing the collagen carrier to reduce the thickness of the collagen carrier.66. A process according to claim 61 , further comprising arranging the form-stable coiled collagen carrier in a container and subsequently sealing the container.67. A coiled collagen carrier obtainable by the process of .68. A method of surgery comprising administering to a patient in need thereof the coiled collagen carrier according to .69. A method of preventing or treating an injury associated with performing minimally invasive surgery in a patient claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .70. A method of preventing or treating an injury associated with performing endoscopic surgery in a patient claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .71. A method of preventing injury to or treating a tissue in need of sealing and/or glueing claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .72. A coiled collagen ...

Подробнее
Номер записи: 7
13-03-2014 дата публикации

RAPIDLY ACTING DRY SEALANT AND METHODS FOR USE AND MANUFACTURE

Номер: US20140072614A1
Автор: Osawa A. Edward, Reich Cary J., Rhee Woonza M., Vega Felix
Принадлежит:

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties. 1. A method of treating a tissue of an individual , the method comprising:applying a sealant composition to the tissue of the individual, the sealant composition comprising a first component having a nucleophilic polymer and a second component having an electrophilic polymer, wherein the first component and the second component are fixed on a support comprising a member selected from the group consisting of a protein, a carbohydrate, and a synthetic polymer.2. The method according to claim 1 , wherein each of the first and second components is present as a gel.3. The method according to claim 1 , wherein the sealant composition further comprises a hydrogel-forming component fixed on the support.4. The method according to claim 3 , wherein the hydrogel forming component comprises a biologic polymer selected from the group consisting of gelatin claim 3 , collagen claim 3 , albumin claim 3 , hemoglobin claim 3 , fibrogen claim 3 , fibrin claim 3 , casein claim 3 , fibronectin claim 3 , elastin claim 3 , keratin claim 3 , laminin claim 3 , and derivatives and combinations thereof.5. The method according to claim 1 , wherein the support is porous and comprises a member selected from the group consisting of a pad claim 1 , a sheet claim 1 , a film claim 1 , and a sponge.6. The method according to claim 1 , wherein the support comprises a member selected from the group consisting of collagen claim 1 , fibrin claim 1 , cellulose claim 1 , and chitosan.7. The method according to claim 1 , wherein the first component nucleophilic polymer comprises a member selected from the group consisting of a ...

Подробнее
Номер записи: 8
27-03-2014 дата публикации

FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE

Номер: US20140086898A1
Автор: Osawa A. Edward, Qian Zhen, Reich Cary J., Shargill Narinder S., Vega Felix, Wallace Donald G.
Принадлежит:

Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. 1. A method of treating a patient with a hemostatic composition , the method comprising:delivering the hemostatic composition to a treatment site of the patient,wherein the hemostatic composition comprises a mixture containing an amount of thrombin and an amount of resorbable fragmented cross-linked gelatin gel, andwherein the resorbable fragmented cross-linked gelatin gel swells, by absorption of moisture from the treatment site following delivery, to reach an equilibrium swell, the gelatin gel having an equilibrium swell value within a range from 400% to 1300%.2. The method according to claim 1 , wherein the delivery step includes extruding the mixture from a syringe to the treatment site.3. The method according to claim 1 , wherein the treatment site is a bleeding site or bleeding tissue surface of a patient claim 1 , or an abraded or damaged tissue surface of a patient.4. The method according to claim 3 , wherein the tissue surface comprises an organ surface selected from the group consisting of a liver surface claim 3 , a spleen surface claim 3 , a heart surface claim 3 , a kidney surface claim 3 , an intestine surface claim 3 , a blood vessel surface claim 3 , and a vascular organ surface.5. The method according to claim 3 , comprising delivering the hemostatic composition to the bleeding site or ...

Подробнее
Номер записи: 9
03-04-2014 дата публикации

EDIBLE, BIODEGRADABLE FOOD AND BEVERAGE CONTAINER

Номер: US20140093625A1
Автор: BECK Alec A., MAIER Allicen
Принадлежит:

An edible, biodegradable container that includes an edible or biodegradable sealant preventing liquids or moisture from foods or beverages stored therein from being absorbed into the container is disclosed. The sealant allows the edible container to contain liquids, even when the liquids are stored for extended periods of time within the container. The sealant may be applied to the interior of the container only, or may be applied to the entire container. The edible container may be configured in any size and shape to hold a plurality of different foods or beverages such as cups, mugs, shot glasses, bowls, or bottles. The edible container may be formed with high side walls, allowing it to hold a beverage and used like a traditional drinking cup or mug. The edible container is configured to be eaten during or after consumption of the food or liquid stored therein. 1. An edible container for holding food or beverages , the edible container comprising:a base;side walls connected to the base;a top rim formed from the tops of the side walls; anda biodegradable sealant material, wherein the biodegradable sealant material coats at least a portion of the interior of the container and prevents liquids from being absorbed into the edible material.2. The edible container of claim 1 , wherein the edible container is configured in the shape of a cup with high side walls claim 1 , wherein the high side walls have a height greater than the diameter of the base.3. The edible container of claim 1 , further comprising seasonings or flavorings coating at least a portion of the exterior of the edible container.4. The edible container of claim 1 , wherein the biodegradable sealant material comprises a plurality of coatings of biodegradable sealant material.5. The edible container of claim 1 , wherein the biodegradable sealant material is removable.6. The edible container of claim 1 , wherein the biodegradable sealant material is edible.7. The edible container of claim 1 , wherein the ...

Подробнее
Номер записи: 10
07-01-2016 дата публикации

HEMOSTATIC COMPOSITIONS

Номер: US20160000863A1
Автор: MURAT MORENO Jesús, RODRÍGUEZ FERNÁNDEZ-ALBA Juan Ramon
Принадлежит: THROMBOTARGETS EUROPE, S.L

The invention provides a composition comprising a combination of lipidated tissue factor and thrombin, wherein the amount of thrombin is comprised from 1 to 30 IU per gram of composition, and the amount of lipidated tissue factor is comprised from 5 to 150 ng per gram of composition. The present invention also provides pharmaceutical or veterinary compositions as well as hemostatic compositions. The compositions of the invention are useful in the treatment of hemorrhages. 1. A composition comprising a combination of lipidated tissue factor and thrombin , wherein the amount of thrombin is comprised from 1 to 30 IU per gram of composition , and the amount of lipidated tissue factor is comprised from 5 to 150 ng per gram of composition.2. The composition according to claim 1 , wherein the lipidated tissue factor is comprised from 5 to 15 ng per gram of composition.3. The composition according to claim 1 , wherein at least one of the N-glycosilation sites of the tissue factor is non-functional.4. The composition according to claim 1 , wherein said tissue factor is a fusion protein comprising a first portion which comprises the tissue factor protein claim 1 , and a second portion which comprises another peptide or protein.5. The composition according to claim 4 , wherein the second portion is a tag.6. The composition according to claim 4 , wherein the fusion protein has a first portion which comprises the mature human tissue factor protein with at least one of the N-glycosilation sites being non-functional claim 4 , and a second portion which comprises a His-tag.7. The composition according to claim 6 , wherein the fusion protein corresponds to SEQ ID NO: 5.8. The composition according to claim 1 , wherein the TF protein is anchored in a lipid microvesicle.9. A pharmaceutical or veterinary composition comprising a therapeutically effective amount of the composition according to claim 1 , together with other appropriate pharmaceutically or veterinary acceptable excipients ...

Подробнее
Номер записи: 11
07-01-2021 дата публикации

Composition for hemostasis and container comprising same

Номер: US20210001002A1
Автор: Bae Sang-Hee, Ko Jae-Hyung, Park Si-Nae
Принадлежит:

The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat. 1. A composition for hemostasis comprising collagen;stabilizer; andthrombin,wherein the stabilizer is disposed between the collagen and the thrombin so that the collagen and the thrombin are separated from each other.2. The composition of claim 1 , wherein the collagen is crosslinked collagen.3. The composition of claim 2 , wherein the crosslinked collagen is prepared using a preparing method including(S1) a step of treating the collagen with ethanol or methanol,(S2) a step of preparing collagen solution having pH 2 to pH 4 by adding acid to the collagen treated in the step (S1),(S3) a step of preparing esterified collagen by performing centrifugation on the collagen solution prepared in the step (S2) after bringing the collagen solution into a neutral state,(S4) a step of preparing the crosslinked collagen by adding a crosslinking agent to esterified collagen prepared in the step of (S3), and(S5) a step of performing freeze drying on the crosslinked collagen prepared in the step (S4) after the crosslinked collagen is dispersed into purified water.4. The composition of claim 2 , wherein a molecular weight of the crosslinked collagen is 100 claim 2 ,000 to 1 claim 2 ,000 claim 2 ,000 Dalton.5. The composition of claim 1 , wherein the collagen is included as much as 40 to 97 weight % in a gross weight of the composition for hemostasis.6. The composition of claim 1 , wherein the stabilizer is at least one selected from a group consisting of albumin (human serum albumin) claim 1 , ...

Подробнее
Номер записи: 12
04-01-2018 дата публикации

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

Номер: US20180000983A1
Автор: Brandacher Gerald, Brat Gabriel, Grahammer Johanna, Schneider Joel, SMITH Daniel
Принадлежит:

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Подробнее
Номер записи: 13
05-01-2017 дата публикации

Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties

Номер: US20170000923A1
Автор: IFTODE Cristina, JOHNSON Bryan, KADLOWEC Jennifer, KUBINSKI Pamela, TULENKO Thomas N., Vernengo Andrea J., WILTSEY Craig
Принадлежит: ROWAN UNIVERSITY

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection off liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101-. (canceled)102. A method of forming a solidified matrix fixed within the body of a mammal , the method comprising: a) a biocompatible thermally-desolubilizable (TD) polymer selected from the group consisting of poly(ethylene oxides) (PEOs), poly(propylene oxides) (PPOs), copolymers of PEO and poly(lactide acid) (PLA), poly (n-isopropyl acrylamides) (PNIPPAms), mixtures and copolymers thereof, wherein the polymer exists in an extended form below a critical solution temperature (CST) that is lower than the normal body temperature of the mammal and in a condensed form at or above the CST;', 'b) an aminated component of a mammalian extracellular matrix, in a releasable encapsulated form, wherein the aminated component ...

Подробнее
Номер записи: 14
20-01-2022 дата публикации

TWO-REACTANT SHEET-SHAPED ADHESIVE/REINFORCEMENT FOR TISSUES

Номер: US20220016311A1
Автор: FUJIMURA Motoki, Hyon Suong-Hyu, Hyon Woogi, KOJITANI Yusuke, OSADA Shinichi, TANIDA Shuhei
Принадлежит:

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement. 1. A sheet-shaped tissue adhesive/reinforcement comprising:a base sheet having biodegradability and a communicative porous structure; andan adhesive resin layer fixed and formed on the base sheet,the adhesive resin layer includinga first reactant made of aldehyded glycan, anda second reactant made of partially carboxylated polylysine, and the adhesive resin layer havinga molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant,a structure of granules derived from powder of the first reactant, anda connecting layer derived from the second reactant, the connecting layer connecting the granules with each other and fixing each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.2. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , whereinthe base sheet is non-woven fabric, woven fabric, knitted fabric, mesh sheet, sponge sheet, or other continuous porous sheet, and has a thickness of 15 μm to 500 μm, andthe adhesive resin layer has a thickness of 100 μm to 800 μm.3. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , wherein the granules derived from the powder of the ...

Подробнее
Номер записи: 15
12-01-2017 дата публикации

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Номер: US20170007264A1
Автор: Constant Michael J., Cruise Gregory M., Keeley Edward Michael, Tran Terrance T.
Принадлежит:

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Подробнее
Номер записи: 16
12-01-2017 дата публикации

METHODS AND COMPOSITIONS USED IN TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES

Номер: US20170007681A1
Автор: McCarty Owen J., Offner-Vandenbark Halina, Tucker Erik I., Verbout Norah
Принадлежит:

Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation. The pharmaceutical compositions and pharmacological dose comprise a safe and effective amount of WE thrombin. 1. A method of treating neuroinflammation in a subject , the method comprising:administering to the subject a pharmaceutical composition comprising a safe and effective amount of recombinant WE thrombin, or a homolog thereof.2. The method of claim 1 , wherein the amino acid sequence of the WE thrombin is at least 90% identical to SEQ ID NO: 1 and comprises an alanine at positions 215 and 217.3. The method of claim 1 , wherein the amino acid sequence of the WE thrombin is at least 95% identical to SEQ ID NO: 1 and comprises an alanine at positions 215 and 217.4. The method of claim 1 , wherein the amino acid sequence of the WE thrombin is at least 99% identical to SEQ ID NO: 1 and comprises an alanine at positions 215 and 217.5. The method of claim 1 , wherein the amino acid sequence of the WE thrombin comprises or consists of SEQ ID NO: 1.6. The method of claim 1 , wherein the pharmaceutical composition is formulated to be administered intravenously.7. The method of claim 1 , wherein the subject is a primate and the pharmaceutical composition is formulated to deliver a total dose of at least 1.25 μg/kg WE thrombin.8E. coli.. The method of claim 1 , wherein the recombinant WE thrombin is derived from expression in9. The method of claim 1 , wherein the neuroinflammation comprises encephalopathy or demyelination.10. The method of claim 1 , wherein the subject has multiple sclerosis.11. The method of claim 1 , further comprising administering one or more protein C activation cofactors to the subject12. The method of claim 11 , wherein the one ...

Подробнее
Номер записи: 17
14-01-2016 дата публикации

STEM CELL COMPOSITIONS AND METHODS FOR WOULD HEALING

Номер: US20160008506A1
Автор: FALANGA Vincent
Принадлежит:

This application provides compositions for wound repair comprising VSEL stem cells and methods for treating acute and chronic cutaneous wounds, including burns and ulcers. 1. A composition for treating a wound , comprising a matrix and a cellular component;{'sup': 5', '2, 'wherein the cellular component comprises an amount of VSEL stem cells for application to the wound in a dosage of 10or fewer VSEL stem cells/cm.'}2. The composition of claim 1 , wherein the matrix comprises a fibrinogen complex (FC) component and a thrombin component.3. The composition of claim 1 , wherein the VSEL stem cells are obtained from bone marrow claim 1 , peripheral blood claim 1 , cord blood claim 1 , or a combination thereof.4. The composition of claim 1 , wherein the VSEL stem cells are lin/CD45/CD34 claim 1 , lin/CD45/CD133 claim 1 , lin/CD45/CXCR4 claim 1 , or lin/CD45/CXCR4/CD133/CD34.5. The composition of claim 1 , wherein the VSEL stem cells are lin/CD45/Sca-1 or lin/CD45/CD.6. A method of treating a cutaneous wound claim 1 , comprising:{'sup': 5', '2, 'a) combining VSEL stem cells with a fibrin sealant to form a wound sealant; wherein the fibrin sealant comprises calcic thrombin and fibrinogen, wherein the amount of VSELs in the wound sealant provides a dosage of 10or fewer VSEL stem cells/cmwhen administered to the cutaneous wound, and'}b) administering the fibrin sealant to the cutaneous wound.7. The method of claim 6 , which comprises administering the wound sealant at least two times over the span of three weeks.8. The method of claim 6 , wherein the wound sealant is topically applied to the site of the wound.9. The method of claim 6 , wherein the wound sealant is administered to the site of the wound in the form of a spray at a COpsi of less than 5 psi.10. The method of claim 6 , which comprises applying a skin substitute at the site of the wound.11. The method of claim 6 , wherein the wound is the result of a burn.12. The method of claim 6 , wherein the wound is a ...

Подробнее
Номер записи: 18
21-01-2016 дата публикации

POWDER FORMULATION COMPRISING THROMBIN AND FIBRINOGEN

Номер: US20160015792A1
Автор: Hendricus van Pinxteren Laurens Adrianus, Martyn Glen, Whitfield Nicola Kim
Принадлежит:

The invention relates to sterile powder compositions suitable for medical use comprising thrombin and fibrinogen, and to methods for producing the same, wherein the thrombin powder is produced from a liquid feedstock, wherein the feedstock comprises a solution or a suspension of thrombin, preferably a solution, wherein the powder is produced by removal of liquid by a process selected from aseptic spray drying or aseptic fluid bed drying, and wherein the powder resulting from removal of liquid from the feedstock exhibits at least 80% of the thrombin potency or activity of the liquid feedstock, and wherein the fibrinogen powder is produced by removal of liquid from a feedstock, wherein the feedstock comprises a solution or a suspension of fibrinogen, preferably a solution, by aseptic spray drying or aseptic fluid bed drying, and wherein said composition is packaged as a sterile final pharmaceutical product for medical use.

Подробнее
Номер записи: 19
16-01-2020 дата публикации

DEVICE FOR DELIVERY OF POWDERED HEMOSTATIC AGENTS

Номер: US20200016292A1
Автор: BARRY John Joseph Anthony, Fulghum Timothy Michael, HOLSCHER Russel L., SANDERS Paul Jeffrey
Принадлежит:

The disclosure provides a multilayered hemostatic device including a first layer including carboxymethyl cellulose, a second layer including a powdered hemostatic agent provided on the first layer, and a third layer including at least one of gauze, oxidized cellulose, or collagen provided on the second layer, wherein the first layer and the third layer encapsulate the second layer and the hemostatic agent comprises one of fibrinogen, thrombin, fibrin monomers, or the combination of thrombin and gelatin. 1. A multilayered hemostatic device comprising:a first layer comprising carboxymethyl cellulose;a second layer comprising a powdered hemostatic agent provided on the first layer; anda third layer comprising at least one of gauze, oxidized cellulose, or collagen provided on the second layer, wherein the first layer and the third layer encapsulate the second layer,wherein the hemostatic agent comprises one of fibrinogen, thrombin, fibrin monomers, or the combination of thrombin and gelatin.2. The multilayered hemostatic device of claim 1 , wherein the powdered hemostatic agent is a solid particulate.3. The multilayered hemostatic device of or claim 1 , wherein the powdered hemostatic agent is provided on the first layer in a repeating pattern.4. The multilayered hemostatic device of any one of the preceding claims claim 1 , wherein the first layer and the third layer have perimeter edges and the first layer and third layer are sealed along the perimeter edges.5. The multilayered hemostatic device of claim 4 , wherein the perimeter edges of the first layer and the third layer are heat sealed.6. The multilayered hemostatic device of claim 4 , wherein the perimeter edges of the first layer and the third layer are solvent sealed.7. The multilayered hemostatic device of any one of the preceding claims claim 4 , wherein the first layer is soluble under physiological conditions claim 4 , such that the first layer will dissolve when in contact with a fluid from a wound.8. The ...

Подробнее
Номер записи: 20
28-01-2016 дата публикации

BIOADHESIVE HYDROGELS

Номер: US20160022862A1
Автор: Alsberg Eben
Принадлежит:

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer. Bioadhesives are natural or synthetic materials that can be used for soft tissue repair to create a seal preventing leakage of biological fluids or to reinforce anatomic integrity as an attractive alternative to sutures and staples. The most widely used bioadhesives are fibrin, cyanoacrylates, and albumin-glutaraldehyde bioadhesives. 1. A bioadhesive comprising: a crosslinked biodegradable hydrogel that includes a plurality of oxidized , acrylated or methacrylated , natural polymer macromers crosslinked with a plurality of branched poly(ethylene glycol) macromers.2. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers include a plurality of aldehyde groups that are crosslinked with the branched poly(ethylene glycol) macromers.3. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers are polysaccharides claim 1 , which are oxidized so that about 1% to about 50% of the saccharide units therein are converted to aldehyde saccharide units.4. The bioadhesive of claim 1 , wherein acrylate or methacrylate groups of the natural polymer macromers are crosslinked so that the hydrogel is dual crosslinked.5. The bioadhesive of claim 1 , the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers comprising oxidized claim 1 , acrylated or methacrylated claim 1 , alginates.6. The bioadhesive of claim 1 , wherein the poly(ethylene glycol) macromers are poly(ethylene glycol) amine macromers.7. The bioadhesive of claim 6 , wherein the poly(ethylene glycol) amine macromers are n-arm poly(ethylene glycol) amines claim 6 , where n is an integer greater than 1.8. The bioadhesive of claim 1 , wherein the hydrogel is cytocompatible and claim 1 , upon degradation claim 1 , produces ...

Подробнее
Номер записи: 21
28-01-2016 дата публикации

ENCLOSING MATERIALS IN NATURAL TRANSPORT SYSTEMS

Номер: US20160023826A1
Автор: Edwards David A., Lamppa John A., Vaughn Jeffrey L.
Принадлежит:

An edible composition, particularly an edible transport system, can be an edible substance and a cross-linked matrix encapsulating the edible substance, the cross-linked matrix comprising (1) at least one edible polymer and edible particles or (2) a plurality of edible polymers. 1. An edible transport system , comprising:an edible or potable substance; anda cross-linked matrix encapsulating the edible or potable substance, the cross-linked matrix comprising at least two different edible polymers.2. The edible transport system of claim 1 , wherein the at least two different edible polymers are charge cross-linked by multivalent ions claim 1 , including cross-linking interactions between the edible particles and edible polymer or plurality of edible polymers via bridges formed by the multivalent ions.3. The edible transport system of claim 1 , wherein the at least two different edible polymers selected from the group consisting of a positively charged edible polymer claim 1 , a neutrally charged edible polymer claim 1 , a negatively charged edible particle claim 1 , an amphipathic edible polymer claim 1 , a zwitterionic edible polymer claim 1 , and combinations thereof.4. The edible transport system of claim 1 , wherein the at least two different edible polymers comprise polysaccharides selected from the group consisting of a hydrocolloid claim 1 , shellac claim 1 , and fibers.5. The edible transport system of claim 4 , wherein the at least two different edible polymers comprise a hydrocolloid selected from the group consisting of an alginate claim 4 , an agar claim 4 , a starch claim 4 , a gelatin claim 4 , carrageenan claim 4 , xanthan gum claim 4 , gellan gum claim 4 , galactomannan claim 4 , gum arabic claim 4 , a pectin claim 4 , a milk protein claim 4 , a cellulosic claim 4 , a carboxymethylcellulosic claim 4 , a methylcellulosic claim 4 , gum tragacanth and karaya claim 4 , xyloglucan claim 4 , curdlan claim 4 , a cereal β-glucan claim 4 , soluble soybean ...

Подробнее
Номер записи: 22
28-01-2021 дата публикации

CEREBROSPINAL FLUID LEAKAGE OCCLUSION

Номер: US20210023257A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions. 1. (canceled)2. A method for treating cerebrospinal fluid leakage , the method comprising administering an effective amount of a self-assembling peptide solution to an area of dura associated with the cerebrospinal fluid leakage , wherein the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions;{'sup': 2', '2, 'wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof a site of the cerebrospinal fluid leakage; and'}the self-assembling peptide is about 0.1 to about 3.5 w/v % of the self-assembling peptide solution.3. The methods of claim 1 , wherein the target area comprises an area of dura associated with cerebrospinal fluid leakage.4. The method of claim 1 , wherein the hydrogel mitigates cerebrospinal fluid leakage.5. The method of claim 1 , wherein the hydrogel substantially prevents cerebrospinal fluid leakage.6. The method of claim 2 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and-a hydrophilic amino acids.7. The method of claim 2 , wherein the self-assembling peptide comprises a sequence selected from RADA (SEQ ID NO:1) claim 2 , IEIK (SEQ ID NO:2) claim 2 , TTTT (SEQ ID NO:3) claim 2 , ATAT (SEQ ID NO:4) claim 2 , TVTV (SEQ ID NO:5) claim 2 , ASAS (SEQ ID NO:6) claim 2 , SSSS (SEQ ID NO:7) claim 2 , VVVTTTT (SEQ ID NO:8) claim 2 , and a combination thereof.8. ...

Подробнее
Номер записи: 23
28-01-2021 дата публикации

POLY (IONIC LIQUID) COMPOSITIONS AND THEIR USE AS TISSUE ADHESIVES

Номер: US20210023259A1
Автор: NOSHADI Iman
Принадлежит:

The present invention relates to the discovery of methods of treating a wound in a subject in need thereof. In certain embodiments, the method comprises contacting the wound with a composition comprising gelatin methacrylate and choline acrylate, and then polymerizing the composition to form a polymerized composition having a plurality of choline acrylate functionalized gelatin methacrylate units. 1. A method of treating a wound in a subject in need thereof , the method comprising:(a) contacting the wound with a composition comprising:a polymer selected from the group consisting of gelatin methacrylate (GelMa) and poly(ethylene glycol) diacrylate (PEGDA);choline acrylate; andat least one photoinitiator; and(b) exposing the composition to at least one wavelength of light capable of activating the at least one photoinitiator, thereby polymerizing the composition.2. The method of claim 1 , wherein the composition comprises about 1:4 to about 4:1 choline acrylate to polymer.3. (canceled)4. The method of claim 1 , wherein at least one photoinitiator is selected from the group consisting of eosin Y claim 1 , 2-hydroxy-2-methylpropiophenone claim 1 , 2-methyl-4′-(methylthio)-2-morpholinopropiophenone claim 1 , lithium phenyl-2 claim 1 ,4 claim 1 ,6-trimethylbenzoylphosphinate (LAP) claim 1 , and 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure).5. The method of claim 1 , wherein the composition further comprises at least one additional compound selected from the group consisting of triethanolamine (TEOA) and N-vinylcaprolactam (VC).6. (canceled)7. The method of claim 1 , wherein the composition comprises about 10% to about 20% (w/v) choline acrylate.8. The method of claim 1 , wherein the composition comprises about 10% to about 30% (w/v) polymer.9. The method of claim 4 , wherein the composition comprises at least one of:about 0.1 mM eosin Y;0.5% (w/v) LAP;about 1.5% (w/v) TEOA; orabout 1% (w/v) VC.10. (canceled)11. (canceled)12. (canceled)13. The method of ...

Подробнее
Номер записи: 24
29-01-2015 дата публикации

Methods and Compositions for Treating Wounds and Reducing the Risk of Incisional Hernias

Номер: US20150030678A1
Автор: Harris Hobart W.
Принадлежит: The Regents of the University of California

Provided are methods and compositions for treating a wound in a subject. The methods include applying a pharmaceutical composition that includes a first precursor material agent including fibrinogen, a second precursor material agent including thrombin, and silver particles to an abdominal incision site in an amount effective to treat the abdominal incision site. Also provided are pharmaceutical compositions and devices for use in the subject methods. 1. A method for treating a wound in a subject , the method comprising:applying a pharmaceutical composition comprising a first precursor material agent comprising fibrinogen, a second precursor material agent comprising thrombin, and silver particles to an abdominal incision site in an amount effective to treat the abdominal incision site.2. The method of claim 1 , wherein the first precursor material agent claim 1 , the second precursor material agent and the silver particles are adapted to be combined in situ.3. The method of claim 1 , wherein the applying comprises applying the first precursor material agent prior to applying the second precursor material agent.4. The method of claim 1 , wherein the applying comprises applying the second precursor material agent prior to applying the first precursor material agent.5. The method of claim 1 , wherein the silver particles are silver microparticles.6. The method of claim 5 , wherein the silver particles are spherical.7. The method of claim 5 , wherein the silver microparticles have an average diameter of 5 μm or more.8. The method of claim 7 , wherein the silver microparticles have an average diameter of 200 μm or more.9. The method of claim 1 , wherein the pharmaceutical composition comprises 25 mg/mL silver particles.10. The method of claim 1 , wherein the pharmaceutical composition comprises 250 mg/mL silver particles.11. A pharmaceutical composition for treating a wound in a subject claim 1 , the composition comprising:a fibrin glue and silver particles in an amount ...

Подробнее
Номер записи: 25
04-02-2016 дата публикации

TREATMENT FOR BILE LEAKAGE

Номер: US20160030628A1
Автор: Kobayashi Satoru
Принадлежит: 3-D Matrix, Ltd.

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Подробнее
Номер записи: 26
01-02-2018 дата публикации

CARBON-BASED COMPOSITIONS USEFUL FOR OCCLUSIVE MEDICAL DEVICES AND METHODS OF MAKING AND USING THEM

Номер: US20180028715A1
Автор: Eisenfrats Kevin
Принадлежит:

An occlusive device and a method of embolizing or occluding a bodily lumen by injecting or otherwise implanting the occlusive device are described. The device includes a polymer or polymer composition and a carbon-based material or nanomaterial such as graphene. The device may be used for sterilizing a human or animal by implanting the device into the vas deferens, fallopian tubes, or uterus, but may also be used to occlude any other bodily ducts, interstitial space, or organs. 1. A composition comprising:a carbon-based nanomaterial or carbon allotrope, a polymer or network forming agent, and a solvent,wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which enhances the efficacy of the composition as an occlusive agent upon administration into a body lumen.2. The composition of claim 1 , wherein the composition is a hydrogel or forms a hydrogel in situ upon administration into a body lumen.3. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which enhances the efficacy of the composition as a contraceptive agent.4. The composition of claim 3 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that decreases the fertility claim 3 , motility claim 3 , and/or viability of sperm cells.5. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that increases the hardness and/or durability of the hydrogel.6. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that improves the mechanical properties of the hydrogel.7. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which alters the viscosity of the hydrogel.8. The composition of ...

Подробнее
Номер записи: 27
01-05-2014 дата публикации

FRAGMENTED POLYMERIC COMPOSITIONS AND METHODS FOR THEIR USE

Номер: US20140120078A1
Автор: Osawa A. Edward, Reich Cary J., Shargill Narinder S., Vega Felix, Wallace Donald G.
Принадлежит:

Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like. 1. A kit comprising:a composition comprising a sterile biocompatible resorbable molecular cross-linked gel;written instructions to apply the gel onto a target site on tissue; anda container holding the composition and the written instructions.2. A kit according to claim 1 , wherein the gel is dehydrated.3. A kit according to claim 1 , wherein the gel is hydrated.4. The kit according to claim 1 , wherein the gel biodegrades in a patient's body in a time period ranging from 2 to 30 days.5. (canceled)6. The kit according to claim 1 , wherein the gel has an equilibrium swell ranging from 500% to 1100%.7. The kit according to claim 1 , wherein the kit further comprises a bioactive component.8. The kit according to claim 7 , wherein the bioactive component is a hemostatic agent.9. The kit according to claim 8 , wherein the hemostatic agent is thrombin.10. The kit according to claim 1 , wherein the kit further comprises an aqueous medium.11. The kit according to claim 1 , wherein the kit further comprises a tray.12. A kit comprising:(a) a sterile package; (i) a syringe; and', "(ii) an amount of a resorbable fragmented cross-linked gelatin gel present in the syringe, wherein the gel biodegrades in a patient's body in a time period ranging from 1 to 90 days and has an equilibrium swell ranging from 400% to 1300%; and ...

Подробнее
Номер записи: 28
01-05-2014 дата публикации

Gelatin Sponge Comprising an Active Ingredient, Its Preparation and Use

Номер: US20140120151A1
Автор: Bar Liliana, Nur Israel, Sheetrit Eyal, Tomer Guy
Принадлежит:

The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof. 115-. (canceled)16. An improved dry cross-linked gelatin sponge comprising a layer of a protein or peptide active ingredient on at least one surface of the sponge , the layer having an average thickness of not more than about 24% of the overall thickness of the sponge , wherein said layer is stable and is substantially homogenously distributed throughout said surface; and the thickness and the flexibility of the sponge are substantially similar to those found in the original counterpart non-layered gelatin sponge.17. The sponge according to claim 16 , wherein wetting agents are absent from said layer.18. The sponge according to or claim 16 , wherein the active ingredient comprises thrombin.19. The sponge according to claim 18 , wherein the thrombin activity is in the range of from about 1 to about 300 IU/cm claim 18 , in the range of from about 10 to about 40 IU/cm claim 18 , or in the range of from about 20 to about 40 IU/cm.20. The sponge according to any one of to for use in surgery.21. The sponge according to for promoting blood coagulation.22. A package containing a sterile cross-linked gelatin sponge according to any one of the to .2324-. (canceled) The invention relates to an improved dry and flexible cross-linked gelatin sponge comprising a layer of active ingredient and uses thereof.Rapid blood loss from relatively large surfaces is particularly difficult to control since it cannot be ...

Подробнее
Номер записи: 29
05-02-2015 дата публикации

Systems, Devices, Components and Methods for Improved Acoustic Coupling Between a Bone Conduction Hearing Device and a Patient's Head or Skull

Номер: US20150038775A1
Автор: Ruppersberg Peter
Принадлежит: SOPHONO, INC.

Disclosed are various embodiments of systems, devices, components and methods for improving acoustic coupling between a bone conduction hearing device (BCHD) and a patient's head or skull. Such systems, devices, components and methods include disposing a gel or paste between the BCHD and the patient's skin, hair and/or skull. The gel or paste improves the transmission of acoustic signals generated by a transducer in the BCHD to the patients head or skull by providing a more efficient and improved intermediary acoustic medium for the transmission of acoustic signals to the patient's head or skull. 1. A method of improving acoustic coupling between a bone conduction hearing device (BCHD and a patient's head or skull , the BCHD comprising a transducer configured to generate sound signals for transmission to the patient's skull , the method comprising:applying an aqueous gel or paste to a bottom surface of the BCHD, andattaching, securing or magnetically coupling the BCHD to or against the patient's head or skull;wherein at least portions of the gel or paste are operably disposed between the bottom surface of the BCHD and the patient's head or skull thereby to improve acoustic coupling and transmission of the sound signals generated the transducer to the patient's skull.2. The method of claim 1 , wherein a baseplate or spacer is operably connected to or forms a portion of the BCHD and is operably attached to or forms a portion of the transducer.3. The method of claim 1 , wherein the transducer is an electromagnetic (“EM”) transducer or a piezoelectric transducer.4. The method of claim 1 , wherein the BCHD is a magnetic BCHD.5. The method of claim 4 , wherein a magnetic implant is attached to or in the patient's skull beneath the patient's skin at an implant location claim 4 , and is configured to magnetically couple to the magnetic BCHD.6. The method of claim 5 , wherein the magnetic BCHD is magnetically attached to the patient's skull over the implant location.7. The ...

Подробнее
Номер записи: 30
09-02-2017 дата публикации

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

Номер: US20170035929A1
Автор: Garner John, Phillips Victor Matthew
Принадлежит:

A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site. 1. A method of inhibiting bleeding from an open surgical site , said method comprising:mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition; andapplying the flowable hemostatic gel composition to the open surgical site, wherein the cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.2. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution within a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.3. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution prior to introducing the flowable hemostatic gel composition into a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.4. The method of claim 1 , wherein said mixing the flowable gel solution ...

Подробнее
Номер записи: 31
13-02-2020 дата публикации

FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL

Номер: US20200046877A1
Автор: Aklyama Yusuke, Fujinaga Kentaro, HIRASHIMA MASAKI, HONDA Susumu, Imamura Takayuki, Kageyama Yukako, Kaneko Hiroaki, Kawamura Ryoichi, OONO Akitoshi, Satake Makoto, YAMAGUCHI Ayuko
Принадлежит:

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. 1. A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water soluble polymer , wherein at least one part of said at least one protein is incorporated into and is not covalently bonded to said at least one polymer , andwherein the formed sheet product is manufactured from a suspension composed of a solution of the polymer and particles of the protein.2. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of a cellulose derivative claim 1 , a polymer having an N-vinyl cyclic lactam unit claim 1 , polyethylene oxide claim 1 , polyvinyl alcohol claim 1 , hyaluronic acid claim 1 , dextran claim 1 , pullulan claim 1 , starch claim 1 , and a mixture thereof.3. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose claim 1 , and a mixture thereof.4. The ...

Подробнее
Номер записи: 32
08-05-2014 дата публикации

FUNCTIONALIZED ADHESIVE MEDICAL GEL

Номер: US20140128497A1
Автор: Gravagna Philippe, Ladet Sébastien
Принадлежит: SOFRADIM PRODUCTION

A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. A method for adhering a medical gel to biological tissue includes providing a medical gel or a medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members on the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue. 1. A bioadherent substrate comprising a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the medical gel , said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from the group consisting of Huisgen cycloaddition reaction , a Diels-Alder reaction and a thiol-ene reaction.2. The bioadherent substrate according to wherein the medical gel is a hydrogel.3. The bioadherent substrate according to wherein the plurality of reactive members of the specific binding pair are selected from the group consisting of alkynes and azides.4. The bioadherent substrate according to wherein the plurality of reactive members of the specific binding pair form covalent bonds via a reaction catalyzed by copper to activate an alkyne and ...

Подробнее
Номер записи: 33
04-03-2021 дата публикации

System and Methods For Sealing a Channel In Tissue

Номер: US20210059654A1
Автор: McGarvey Colm, Ryan Garrett
Принадлежит:

A system for performing a minimally invasive percutaneous procedure comprises a medical device comprising a hydrogel delivery needle () with a tip and a hydrogel outlet (), an injectable, shear-thinning, self-healing viscoelastic hydrogel that exhibits a storage modulus (G) of at least 600 Pa, and a tan δ (G″/G) from 0.1 to 0.6 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25° C. The system may also comprise a coaxial cannula () having a lumen configured for receipt of the hydrogel delivery needle (), wherein the hydrogel delivery needle comprises an adjustable positioning mechanism () configured to limit the advancement depth of the hydrogel delivery needle through the coaxial cannula to a predetermined depth distal to a distal-most end of the coaxial cannula. 1. A system for sealing a channel in tissue created during a minimally invasive percutaneous procedure , comprising:{'b': 4', '5', '6', '2', '4, 'a medical device comprising a hydrogel delivery needle () with a piercing tip () and a hydrogel outlet (), and a coaxial cannula () having an inner lumen configured for receipt of the hydrogel delivery needle (), and'}an injectable viscoelastic shear-thinning hydrogel.2. A system according to claim 1 , in which the injectable viscoelastic shear-thinning hydrogel exhibits a storage modulus (G′) of at least 400 Pa and a tan δ (G″/G′) from 0.1 to 0.8 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25° C.3. A system according to any preceding claim claim 1 , in which the injectable viscoelastic shear-thinning hydrogel exhibits a compressive modulus of greater than 200 Pa measured at a strain rate of 3 mm/min.4. A system according to any preceding claim claim 1 , in which the shear-thinning viscoelastic hydrogel is configured to exhibit an in-vivo residence time of at least 1 week.5645. A system according to any preceding claim claim 1 , in which the hydrogel outlet () is disposed on a side of the ...

Подробнее
Номер записи: 34
15-05-2014 дата публикации

Collecting device for body fluids

Номер: US20140135720A1
Автор: BACH Anders, Buus Hasse, Stroebech Esben
Принадлежит: COLOPLAST A/S

A body waste collecting device includes a collecting pouch and an adhesive wafer for attachment to the body. The adhesive wafer includes a backing layer, a first adhesive and a second adhesive. The second adhesive includes a polar plasticising oil or a combination of polar plasticising oils in the content of above 10% (w/w) of the second adhesive, and at least one polar polyethylene copolymer, where the content of the polyethylene copolymer is 10-50% (w/w) of the second adhesive, and the polyethylene copolymer has a melt flow index below 2 g/10 min (190° C./21.1N). 2. The collecting device according to claim 1 , wherein the second adhesive in continuous form exhibiting a moisture vapour transmission rate of at least 100 g/m/day for a 150 μm adhesive sheet when measured according to MVTR Test Method.3. The collecting device according to claim 1 , wherein the polar polyethylene copolymer is selected from the group consisting of ethylene vinyl acetate claim 1 , ethylene vinyl acetate carbon monoxide claim 1 , ethylene butyl acetate claim 1 , ethylene vinyl alcohol claim 1 , ethylene butyl acrylate claim 1 , ethylene butyl acrylate carbon monoxide claim 1 , and combinations thereof.4. The collecting device according to claim 3 , wherein the polar polyethylene copolymer is ethylene vinyl acetate.5. The collecting device according to claim 4 , wherein the ethylene vinyl acetate has a content of at least 40% (w/w) vinyl acetate preferably with 40-80% (w/w) vinyl acetate.6. The collecting device according to claim 1 , wherein the content of the polar polyethylene copolymer is 10-45% (w/w) of the second adhesive preferably 15-30%.7. The collecting device according to claim 1 , wherein the polar polyethylene copolymer has a molecular weight of above 250 claim 1 ,000 g/mol.8. The collecting device according to claim 1 , wherein the polar plasticising oil is selected from the group of liquid rosin derivatives claim 1 , aromatic olefin oligomers claim 1 , vegetable and animal ...

Подробнее
Номер записи: 35
04-03-2021 дата публикации

METHOD OF TARGETING EXOSOMES

Номер: US20210062143A1
Автор: Bauzon Maxine, Contag Christopher H., HARDY Jonathan, HERMISTON Terry, KANADA Masamitsu
Принадлежит: GLADIATOR BIOSCIENCES, INC.

The present disclosure relates to a method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method disclosed herein. 2. A method according to claim 1 , wherein the extracellular vesicle is an exosome.3. A method according to claim 2 , wherein the exosome has a diameter in the range 30 nm to 100 nm.4. A method according to claim 1 , wherein the vesicle has a density in the range 1 to 1.5 g/ml claim 1 , such as 1 to 1.2 g/ml claim 1 , in particular 1.13 to 1.19 g/ml.5. A method according to claim 1 , wherein the vesicle comprises one or more transmembrane proteins independently selected from Lamp-1 claim 1 , Lamp-2 claim 1 , CD 13 claim 1 , CD86 claim 1 , Flotillin claim 1 , Syntaxin-3 claim 1 , CD2 claim 1 , CD36 claim 1 , CD40 claim 1 , CD40L claim 1 , CD41a claim 1 , CD44 claim 1 , CD45 claim 1 , ICAM-1 claim 1 , Integrin alpha4 claim 1 , LiCAM claim 1 , LFA-1 claim 1 , Mac-1 alpha and beta claim 1 , Vti-IA and B claim 1 , CD3 epsilon and zeta claim 1 , CD9 claim 1 , CD18 claim 1 , CD37 claim 1 , CD53 claim 1 , CD63 claim 1 , CD81 claim 1 , CD82 claim 1 , CXCR4 claim 1 , FcR claim 1 , GluR2/3 claim 1 , HLA-DM (MHC II) claim 1 , immunoglobulins claim 1 , MHC-I or MHC-II components claim 1 , TCR beta claim 1 , tetraspanins and combinations of two or more of the same.6. A method according to claim 1 , wherein the vesicle was released from an unhealthy cell.7. A method according to claim 6 , wherein the cell is a cancer cell.8. A method according to claim 7 , wherein the cell is a cancer stem cell.9. A method according to claim 1 , wherein the fluid comprises an ex vivo patient sample.10. A method according to claim 1 , wherein GLA domain or active fragment thereof is independently selected from thrombin claim 1 , factor VII claim 1 , factor IX claim 1 , factor X claim 1 , protein C claim 1 , protein S claim 1 , protein Z claim 1 , Osteocalcin claim 1 , Matrix GLA protein claim 1 , ...

Подробнее
Номер записи: 36
10-03-2016 дата публикации

FREE-STANDING BIODEGRADABLE PATCH

Номер: US20160067318A1
Автор: Bonan Raoul, Hakimimehr Dorna
Принадлежит: Bioinspire Technologies, Inc.

Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents. 131-. (canceled)32. A radio-opaque device comprising:a film configured to form a biocompatible, biodegradable patch adapted to adhere to biological tissue upon exposure to an aqueous environment, the film comprising a radiopaque material that renders the film radiopaque,wherein the film is free-standing without a support structure.33. The device of claim 32 , wherein the film further comprises calcium salt.34. The device of claim 33 , wherein the calcium salt comprises calcium chloride.35. The device of claim 32 , wherein the film comprises two layers claim 32 , one layer being an adhesive layer.36. The device of claim 32 , wherein the film comprises two layers claim 32 , one layer comprising the radiopaque material.37. The device of claim 32 , wherein the film further comprises solid fibrinogen.38. The device of claim 37 , wherein the film further comprises thrombin mixed with the solid fibrinogen.39. The device of claim 32 , wherein the device is further configured to release at least one of chemotherapy and an anti-cancer drug.40. The device of claim 32 , wherein the device further comprises a ...

Подробнее
Номер записи: 37
15-03-2018 дата публикации

STABLE PHARMACEUTICAL FOAM

Номер: US20180071358A1
Автор: AUERBACH-NEVO Tamar, DeAnglis Ashley, Nur Israel
Принадлежит:

Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof. 1. A pharmaceutical foam composition comprising a peptone prepared by enzymatic hydrolysis of a full-length protein , wherein said foam is free of said full-length protein.2. The pharmaceutical foam composition according to claim 1 , wherein said peptone comprises peptides of size less than 10.0 kDa.3. The pharmaceutical foam composition according to claim 1 , wherein said foam is stable.4. The pharmaceutical foam composition according to claim 1 , wherein said peptone is present in the foam at a concentration of higher than about 0.05 to lower than about 20% w/v of the foam optionally claim 1 , at a concentration of higher than about 1.5 to lower than about 18.0% w/v of the foam.5. The pharmaceutical foam composition according to claim 1 , further comprising fibrin and/or fibrinogen optionally claim 1 , at a concentration in the range of from about 0.1 mg/mL to about 10 mg/mL of the foam claim 1 , such as at a concentration in the range of from about 2.3 mg/mL to about 7 mg/mL of the foam.6. The pharmaceutical foam composition according to claim 5 , further comprising thrombin optionally claim 5 , at a concentration in the range of from about 0.1 IU/mL to about 100 IU/mL of the foam.7. A method for preparing a pharmaceutical foam composition claim 5 , comprising a step of: foaming a solution of a peptone with a gas claim 5 , the solution of the peptone prepared by enzymatic hydrolysis of a full-length protein in an aqueous solution claim 5 , wherein said solution of the peptone is free of said full-length protein.8. A pharmaceutical foam obtained according to the method of .9. A method for promoting blood coagulation; sealing; prevention and/or reduction of adhesion; and/or wound healing comprising application of a pharmaceutical foam ...

Подробнее
Номер записи: 38
24-03-2022 дата публикации

Bioadhesive hydrogels

Номер: US20220088264A1
Автор: Eben Alsberg, Oju Jeon
Принадлежит: CASE WESTERN RESERVE UNIVERSITY

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.

Подробнее
Номер записи: 39
07-03-2019 дата публикации

Thrombin Microcapsules, Preparation and Uses Thereof

Номер: US20190070270A1
Автор: Gershonovitch Assaf, ILAN Erez, Kaufman Rivka
Принадлежит:

Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof. 119-. (canceled)21. The method according to claim 20 , wherein said evaporating is carried out by a drying gas set to a flow rate of 0.1 to about 1.0 m3/min and heating said gas to a temperature ranging from about 100 to about 170° C.22. The method according to claim 21 , wherein said setting and said heating are carried out sequentially.23. The method according to claim 21 , wherein said drying gas flow rate is set from about 0.3 to about 0.6 m3/min.24. The method according to claim 20 , further comprising cooling the thrombin microcapsules by exposure to a cold gas flow. The invention relates to the field of pharmaceuticals, and more specifically to a spray-dried thrombin powder comprising microcapsules, methods of preparation thereof and uses thereof.Thrombin is a proteolytic enzyme having multiple functions in blood coagulation. Thrombin is formed from prothrombin (coagulation Factor II), a circulating zymogen precursor protein in the plasma. It is proteolytically cleaved to form thrombin in the coagulation cascade. Thrombin in turn acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, as well as catalyzing many other coagulation-related reactions.Thrombin is widely used in clinical applications as a coagulation factor to staunch bleeding of wounds by conversion of fibrinogen to fibrin. It is a common component of surgical dressings, and has been used in combination with fibrinogen and other coagulation proteins in two-component hemostatic systems such as fibrin glues, adhesives, and sealants.Thrombin powder for use in preparation of pharmaceutical compositions is commonly prepared by lyophilization of a solution.The term “lyophilization” typically refers to the process of freezing a solution and then reducing the concentration of water e.g. by sublimation to levels which do not support biological or chemical ...

Подробнее
Номер записи: 40
07-03-2019 дата публикации

OILY COMPOSITIONS

Номер: US20190070332A1
Автор: CAINE Marcus Gordon, CHUNG Shui Ting, DREHER Matthew R., LEWIS Andrew Lennard, Willis Sean Leo
Принадлежит: BIOCOMPATIBLES UK LIMITED

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy. 1. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles comprise a polymer to which iodine is covalently bound.2. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles are sufficiently hydrophobic such that an emulsion prepared according to example 2 herein, using a lipiodol:aqueous phase ratio of 2:1 and in which the aqueous phase contains no contrast agent, is stable for at least 10 minutes at between 18 and 22° C.3. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles, when measured according to Example 4a herein, have a cantilever deflection (measured in volts) of less than that of DC Bead.4. A composition according wherein the particles comprise a polymer to which iodine is covalently bound.5. A composition according to wherein the iodine is bound to an aromatic group claim 1 , which aromatic group is covalently bound to the polymer.6. A composition according to wherein particles comprise a polymer to which iodine is covalently bound claim 1 , and wherein the iodine is present in the particles at a level of at least 30 mg I/ml of packed volume claim 1 , preferably 60 mg iodine per ml PV.7. ...

Подробнее
Номер записи: 41
17-03-2016 дата публикации

PRE-COATED SEASONING BAGS

Номер: US20160075494A1
Автор: Carroll Chris
Принадлежит: Flavorseal LLC

A seasoning bag for seasoning a foodstuff that includes an edible adhesive adhered to an interior of the seasoning bag and a seasoning adhered to the interior of the seasoning bag via the edible adhesive. The seasoning bag may be used in connection the preparation and/or cooking of foodstuffs. The bag may be used to season, marinade, and store a foodstuff. The bag may also be a cook-in bag, suitable for roasting, microwaving, slow cooking, and/or boiling. 120-. (canceled)21. A method for manufacturing a seasoning bag , comprising:expanding a preformed bag;spraying an edible adhesive into an interior of the bag to form an adhesive layer on the interior of the bag; andintroducing a seasoning into the bag such that the seasoning is adhered to the interior of the bag by the adhesive layer.22. The method of claim 21 , wherein the edible adhesive is applied in an amount ranging from about 25 mg per square inch to about 100 mg per square inch.23. The method of claim 21 , wherein the seasoning is applied in an amount ranging from about 25 mg per square inch to about 450 mg per square inch.24. The method of wherein the thickness of the edible adhesive ranges from about 3 mil to about 18 mil and the thickness of the seasoning ranges from about 3 mil to about 18 mil.25. The method of claim 21 , wherein the seasoning forms a liquid marinate when combined with water added to the seasoning bag.26. The method of claim 21 , wherein the seasoning forms a broth when combined with water added to the seasoning bag.27. The method of claim 21 , wherein the seasoning forms a sauce when combined with water added to the seasoning bag.28. The method of wherein the bag is vacuum sealable.29. The method of wherein the bag is at least one of an ovenable bag claim 21 , a boilable bag claim 21 , a slow cooking bag claim 21 , or a microwavable bag.30. The method of claim 21 , wherein the seasoning includes at least one of a coloring additive claim 21 , a nutrient claim 21 , an antimicrobial ...

Подробнее
Номер записи: 42
16-03-2017 дата публикации

HYDROGEL INCLUDING SURFACE-TREATED NANOFIBER AND PREPARATION METHOD THEREOF

Номер: US20170072091A1
Автор: HWANG Dong Soo, Jung Jaehyuk, LEE Do Hoon, Oh Dong Yeop
Принадлежит:

Provided are a bioadhesive hydrogel including surface-treated nanofibers, a preparation method thereof, and use of thereof. The hydrogel including surface-treated nanofibers provided in the present invention may have excellent bioadhesive strength, thereby being widely applied to a bioadhesive, a scaffold for tissue engineering, a carrier for drug delivery, etc. 1. A bioadhesive hydrogel comprising chitin nanofibers or chitosan nanofibers , wherein the nanofibers are surface-treated nanofibers comprising a dihydroxyphenyl moiety , a trihydroxyphenyl moiety , or tannic acid covalently bound to the surface thereof.3. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material having Chemical Formula 1 is selected from the group consisting of gallic acid claim 2 , pyrogallol claim 2 , catechol claim 2 , DOPA (3 claim 2 ,4-dihydroxyphenylalanine) claim 2 , TOPA (3 claim 2 ,4 claim 2 ,5-trihydroxyphenyllalanine) claim 2 , and pyrogallol.4. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material is comprised in an amount of 0.1 to 30% by weight claim 2 , based on 100% by weight of the nanofibers.5. The bioadhesive hydrogel of claim 1 , wherein the hydrogel has an adhesive strength of 5 to 100 Mpa at a relative humidity of 50% claim 1 , and an adhesive strength of 0.05 Mpa to 10 MPa at a relative humidity of 100%.6. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is bioconjugated with a physiologically active substance.7. The bioadhesive hydrogel of claim 6 , wherein the physiologically active substance is a cell claim 6 , a protein claim 6 , a nucleic acid claim 6 , a sugar claim 6 , an enzyme claim 6 , or a mixture thereof.8. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is formed by bonding between the dihydroxyphenyl moiety claim 1 , the trihydroxyphenyl moiety claim 1 , or the tannic acid bound to the chitin nanofibers or the chitosan nanofibers and metal ions by adding the metal ions.9. The bioadhesive ...

Подробнее
Номер записи: 43
16-03-2017 дата публикации

BIOLOGICAL ADHESIVES AND SEALANTS AND METHODS OF USING THE SAME

Номер: US20170072094A1
Автор: BIANCO-PELED Havazelet, KIMHI Ohad, LANGZAM-SINAI Ronit, LEV Rina, MILGROM Charles
Принадлежит:

This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition. 141-. (canceled)42. A kit comprising: a first component and a second component , said first component comprises a crosslinkable polysaccharide and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60 , said second component comprises a crosslinkable polysaccharide and a buffering agent , said buffering agent has a pH value of between 2 to 7 and comprises an acid and its acid addition salt.43. The kit of claim 42 , wherein said crosslinkable polysaccharide is alginate.44. The kit of claim 42 , wherein said crosslinkable polysaccharide and said multivalent cation salt are at a concentration ratio (mg/ml) of 1:1 to 1:4.45. The kit of claim 42 , wherein said multivalent cation salt is selected from:{'sub': 3', '17', '35', '2', '2', '2', '7', '2', '2', '7, 'a calcium salt selected from the group comprising: CaCO, (CHCOO)Ca, CaNaPO, CaPO, or any combination thereof;'}a multivalent cation salt present at a concentration of 20 to 40 mg/ml within said first component; anda particle size between 0.1 microns and 150 microns.46. The kit of claim 42 , wherein said crosslinkable polysaccharide is present at a concentration of 5 to 100 mg/ml within said first component and crosslinkable polysaccharide is present at a concentration of 5 to 100 mg/ml within said second component.47. The kit of claim 42 , wherein said buffering agent has a concentration selected from: a buffering agent having a concentration of between 1 to 2000 mM and a buffering agent having a concentration of 100 to 500 mM.48. The kit of claim 42 , wherein said ...

Подробнее
Номер записи: 44
05-06-2014 дата публикации

METHOD OF PURIFYING THERAPEUTIC PROTEINS

Номер: US20140154233A1
Автор: HEY Jeffrey Michael, NGUY Darren, Pham Hung
Принадлежит: CSL LIMITED

The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof. 3. The method of wherein the first and second hydrophobic charge-induction chromatographic resins are the same.4. The method of claim 1 , further comprising passing the solution comprising fibrinogen and/or Factor VIII and/or VWF recovered in step (ii) through an anion exchange chromatographic resin.5. The method of claim 2 , further comprising passing the solution comprising fibrinogen and/or Factor VIII and/or VWF recovered in step (ii) and/or step (iv) through an anion exchange chromatographic resin.6. The method of claim 1 , further comprising passing the feedstock comprising fibrinogen and/or Factor VIII and/or VWF through an anion exchange chromatographic resin prior to step (i).7. The method of claim 4 , wherein the anion exchange resin is a strong anion exchange resin.8. The method of claim 4 , wherein the solution comprising the fibrinogen and/or Factor VIII and/or VWF is passed through the anion exchange chromatographic resin in the presence of about 170 mM to about 230 mM NaCl.9. ...

Подробнее
Номер записи: 45
12-03-2020 дата публикации

PANCREATIC FISTULA OCCLUSION

Номер: US20200078489A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for occluding a pancreatic fistula are described herein. One method for occluding a pancreatic fistula includes administering an effective amount of a self-assembling peptide solution to a pancreatic fistula, where the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions, thereby occluding the pancreatic fistula. 1. A method for occluding a pancreatic fistula , the method comprising administering an effective amount of a self-assembling peptide solution to a pancreatic fistula , wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions , thereby occluding pancreatic fistula.2. The method of claim 1 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and a hydrophilic amino acids.3. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from RADA claim 1 , IEIK claim 1 , TTTT claim 1 , ATAT claim 1 , TVTV claim 1 , ASAS claim 1 , SSSS claim 1 , VVVTTTT claim 1 , and a combination thereof.4. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from (RADA) claim 1 , (IEIK)I claim 1 , and (KLDL).5. The method of claim 1 , wherein the self-assembling peptide is about 0.1 to about 10 w/v % of the solution or about 0.1 to about 3.5 w/v % of the solution.6. The method of claim 1 , wherein the self-assembling peptide is about 1 claim 1 , about 2.5 claim 1 , or about 3 w/v % of the solution.7. The method of claim 1 , wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof target area.8. The method of claim 1 , wherein the effective amount is approximately 1 mL per 1 cmof target area.9. The method of claim 1 , wherein the hydrogel is formed ...

Подробнее
Номер записи: 46
29-03-2018 дата публикации

Rolled Collagen Carrier

Номер: US20180085322A1
Автор: Bertelsen Poul, Blanka Ingrid, Braender Henrik, Larsen Henrik Neuschaefer, Pedersen Pernille Dybendal, Schoenhofer Wolfgang
Принадлежит:

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery. 160-. (canceled)62. A process according to claim 61 , wherein the coiling is performed by gripping the collagen carrier using at least one pair of tweezers or pincers.63. A process according to claim 61 , wherein at least the coating layer of said collagen carrier is humidified claim 61 , and wherein the coating layer has been humidified using a solvent.64. A process according to claim 63 , wherein the solvent comprises ethanol.65. A process according to claim 61 , further comprising compressing the collagen carrier to reduce the thickness of the collagen carrier.66. A process according to claim 61 , further comprising arranging the form-stable coiled collagen carrier in a container and subsequently sealing the container.68. The method of treating a patient according to claim 67 , wherein the method of treatment further comprises a method of surgery.69. The method of treating a patient according to claim 67 , wherein the method of treatment further comprises a method of treating an injury associated with performing minimally invasive surgery in a patient.70. The method of treating a patient according to claim 67 , wherein the method of treatment further comprises a method of preventing or treating an injury associated with performing endoscopic surgery in a patient.71. The method of treating a patient according to claim 67 , wherein the method of treatment further comprises a method of preventing injury to or treating a tissue in need of sealing and/or glueing.72. The method of treating a patient according to claim 67 , wherein the method of ...

Подробнее
Номер записи: 47
19-06-2014 дата публикации

Process for Producing Dispersible Powders

Номер: US20140167299A1
Автор: Gerstenberger Bernd, Herbert Michael, KILLAT Stefan, Ring Jochen
Принадлежит: Wacker Chemie AG

A process for producing dispersible powders by spray-drying aqueous polymer dispersions and adding antiblocking agent, wherein antiblocking agents present in agglomerated form and having a particle size from 10 μm to 250 μm, or having a particle size from 5 mm to 5 cm in the case of agglomerates in the form of extrudates, are fed in whole or in part by a transport gas into the spray-drying device and are comminuted to a particle size from 0.01 μm to 5 μm, or, in the case of extrudates, to a particle size from 2 μm to 60 μm. 1. A process for producing a dispersion powder by means of spray-drying of aqueous polymer dispersions and addition of antiblocking agent , wherein antiblocking agents present in agglomerated form and having a particle size of 10 μm to 250 μm , or having a particle size of 5 mm to 5 cm in the case of agglomerates in the form of extrudates , are supplied to the spray-drying wholly or partly by means of a conveying gas and are comminuted to a particle size of 0.01 μm to 5 μm or , in the case of extrudates , to a particle size of 2 μm to 60 μm.2. The process as claimed in claim 1 , wherein the comminution of the antiblocking agent is effected by means of an impact mill installed in the conveying line.3. The process as claimed in claim 1 , wherein the comminution of the antiblocking agent is effected by directing the conveying gas laden with antiblocking agent onto one or more impact plates.4. The process as claimed in claim 3 , wherein the impact plate(s) is/are mounted in the antiblocking agent conveying line claim 3 , in the hot air channel and/or in the drying tower.5. The process as claimed in claim 1 , wherein the comminution of the antiblocking agent is effected in a Venturi nozzle.6. The process as claimed in claim 1 , wherein the comminution methods specified in to are performed in any combination.7. The process as claimed in claim 1 , wherein all or some of the antiblocking agent is conveyed into the dryer tower in a conveying line.8. The ...

Подробнее
Номер записи: 48
05-05-2022 дата публикации

PLGA MICROPARTICLES, A SUSTAINED RELEASE FORMULATION THEREOF AND A PRODUCTION METHOD THEREOF

Номер: US20220133632A1
Автор: ARAKI Kaeko, Enomura Masakazu
Принадлежит: M. TECHNIQUE CO., LTD.

The present application provides approximately spherical lactic acid-glycolic acid copolymer (PLGA) microparticles comprising a biologically active substance, wherein an average volume-based particle diameter of the PLGA microparticles is 1 μm or more and 150 μm or less, and a Reactive Span Factor (R.S.F.) of the PLGA microparticles is satisfied with formula (1): 0.1<(R.S.F.)≤1.7 formula (1), wherein an R.S.F. means (D90−D10)/D50; D90 is a particle diameter (μm) corresponding to the cumulative 90% by volume of the cumulative particle diameter distribution from the small particle side; D50 is a particle diameter (μm) corresponding to the cumulative 50% by volume of the cumulative particle diameter distribution from the small particle side; and D10 is a particle diameter (μm) corresponding to the cumulative 10% by volume of the cumulative particle diameter distribution from the small particle side; and an efficient production method thereof. The present invention provides the approximately spherical PLGA microparticles having an average volume-based particle diameter of 1 μm or more and 150 μm or less wherein there are few coarse particles or ultrafine particles without a classification step, and the particle diameter distribution is sharp around the target particle diameter.

Подробнее
Номер записи: 49
12-05-2022 дата публикации

THROMBIN-CARRYING HEMOSTATIC SHEET

Номер: US20220143263A1
Автор: AOKI Megumi, EGAWA Satoru, KIMURA Yasuharu, OGINO Makoto, YOSHIHARA Keiichi, YOSHII Toshitaka
Принадлежит:

Provided is a thrombin-carrying hemostatic sheet that is suitable for hemostasis during surgery, in particular, for hemostasis during spine surgery, that is convenient without preparation before use, and that is bioabsorbable and can be embedded in the body as it is. The hemostatic sheet is composed of a gelatin sponge carrying an effective amount of thrombin, wherein (A) the density is 30 to 55 mg/cm, and (B) the shape maintaining angle in wet conditions is 55 to 120°. 1. A hemostatic sheet comprising a gelatin sponge carrying an effective amount of thrombin ,{'sup': '3', 'wherein A) the hemostatic sheet has a density of 30 to 55 mg/cm, and'}B) when the sheet cut to have a length of 10.0±1.0 mm and a breadth of 20.0±1.0 mm is dipped in physiological saline for 30 minutes, and then, is placed on a horizontally retained cylindrical metal rod having a diameter of 2.0±0.2 mm and a length of greater than or equal to 11.0 mm such that a center line of the sheet in the breadth direction is coincident with the rod, and is left to stand for 5 to 30 seconds, a shape maintaining angle in a wet condition, represented by a spread angle between both ends of the sheet (innermost ends) centered on the metal rod, is 55 to 120 degrees.2. The hemostatic sheet according to claim 1 , wherein the hemostatic sheet has a thickness in a range of 1.0 to 3.5 mm.3. The hemostatic sheet according to claim 1 , wherein the hemostatic sheet has water absorption properties of absorbing 0.1 mL of a phosphate buffer solution dropped on the sheet cut to have a length and a breadth of 10.0±1.0 mm within 10 seconds.4. The hemostatic sheet according to claim 1 , wherein when the hemostatic sheet according to claim 1 , cut to have a weight of 50.0±2.5 mg claim 1 , is put in a conical flask containing a pepsin-hydrochloric acid test solution (80000±8000 U/100 mL) claim 1 , and the conical flask is shaken at a velocity at which an aqueous surface of the pepsin-hydrochloric acid test solution shakes claim 1 ...

Подробнее
Номер записи: 50
28-03-2019 дата публикации

BIOCOMPATIBLE ADHESIVES AND METHODS OF USE THEREOF

Номер: US20190091367A1
Автор: Celiz Adam D., Li Jianyu, Mooney David J.
Принадлежит: President and Fellows of Harvard College

The present invention is directed to a biocompatible adhesive system comprising a) a hydrogel comprising a first polymer network and a second polymer network, wherein the first polymer network comprises covalent crosslinks and the second polymer network comprises ionic crosslinks; b) a high density primary amine polymer; and c) a coupling agent. The present invention also provides methods preparing and using the biocompatible adhesive system. 1. A biocompatible adhesive system comprising:a) a hydrogel comprising a first polymer network and a second polymer network, wherein said first polymer network comprises covalent crosslinks and said second polymer network comprises ionic crosslinks;b) a high density primary amine polymer; andc) a coupling agent.2. The system of claim 1 , wherein the first polymer network is selected from the group consisting of polyacrylamide claim 1 , poly(hydroxyethylmethacrylate) (PHEMA) claim 1 , poly(vinyl alcohol) (PVA) claim 1 , polyethylene glycol (PEG) claim 1 , polyphosphazene claim 1 , collagen claim 1 , gelatin claim 1 , poly(acrylate) claim 1 , poly(methacrylate) claim 1 , poly(methacrylamide) claim 1 , poly(acrylic acid) claim 1 , poly(N-isopropylacrylamide) (PNIPAM) claim 1 , poly(N claim 1 ,N-dimentylacrylamide) claim 1 , poly(allylamine) and copolymers thereof.3. The system of claim 2 , the first polymer network is polyethylene glycol (PEG).4. The system of any one of to claim 2 , wherein the second polymer network is selected from the group consisting of alginate claim 2 , pectate claim 2 , carboxymethyl cellulose claim 2 , oxidized carboxymethyl cellulose claim 2 , hyaluronate claim 2 , chitosan claim 2 , κ-carrageenan claim 2 , ι-carrageenan and λ-carrageenan claim 2 , wherein the alginate claim 2 , carboxymethyl cellulose claim 2 , hyaluronate chitosan claim 2 , κ-carrageenan claim 2 , ι-carrageenan and λ-carrageenan are each optionally oxidized claim 2 , wherein the alginate claim 2 , carboxymethyl cellulose claim 2 , ...

Подробнее
Номер записи: 51
16-04-2015 дата публикации

DEXTRAN-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE

Номер: US20150105346A1
Автор: Lu Helen S.M
Принадлежит: Actamax Surgical Materials, LLC

A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum. 1. A method for applying a coating to an anatomical site on tissue of a living organism comprising:applying to the sitea) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; followed byb) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons; 'or premixing (a) and (b) and applying the resulting mixture to the site.', 'or applying (b) followed by (a) and mixing (a) and (b) on the site;'}2. The method according to wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran a second aqueous solution or dispersion.3. The method according to wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to the total weight of the solution or dispersion.4. The method according to wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.5. The method ...

Подробнее
Номер записи: 52
02-06-2022 дата публикации

VASCULAR EMBOLIC SYSTEM

Номер: US20220168462A1
Автор: Kobayashi Satoru, Takamura Kentaro
Принадлежит: 3-D Matrix, Ltd.

Systems and methods of blocking a biological vessel are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation. 1. A method of blocking one or more targeted biological vessels in a subject comprising:introducing a catheter into a target biological vessel;positioning an end of the catheter in, near, upstream or downstream from a target area of a biological vessel in which at least a partial obstruction of the vessel is desired;administering through the catheter a solution comprising an amphiphilic peptide comprising at least 12 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid in an effective amount and in an effective concentration to form a hydrogel at the target site the hydrogel thereby forming at least a partial blockage of the target biological vessel;removing the catheter from the biological vessel with the at least partial obstruction in place.2. The method of claim 1 , wherein the peptide solution comprises a contrast agent.3. The method of claim 2 , further comprising visualizing a region comprising at least a portion of the targeted biological vessel or vessels.4. The method of claim 3 , wherein visualizing the region comprising at least a portion of the biological vessel comprises visualizing the region during at least one of:identifying the target area of the biological vessel;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andvisualizing the biological vessel after removing the catheter.5. The method of claim 4 , wherein visualizing the region comprises imaging using X-ray radiography.6. The method of claim 3 , wherein visualizing the region provides for ...

Подробнее
Номер записи: 53
04-04-2019 дата публикации

LABEL SYSTEM FOR INGESTIBLE PRODUCTS

Номер: US20190100366A1
Автор: BRUNSON Jeremiah, Burt, JACKSON Damon, JACKSON Tampara Rochelle, JR. EDWARD C.
Принадлежит: Nimbus Health Systems, LLC

A labeling system embodying a label format for ingestible products and method for preventing accidental and/or over-ingestion of infused products is provided. The system facilitates identifying the THC and CBD levels of infused products, providing a clear edible warning label that can be placed directly on the infused edible itself; providing visible identification of infused food products; and providing descriptive content of -related information. 1. An apparatus , comprising:a label configured to be attached to a therapeutic substance, the label formed from an edible material, the label including a machine-readable identification indicium, the indicium including information associated with the therapeutic substance.2. The apparatus of claim 1 , wherein:{'i': 'cannabis', 'the therapeutic substance is a infused product; and'}{'i': 'cannabis', 'the label includes a warning logo indicating that the therapeutic substance has at least a portion of infused therein.'}3cannabis.. The apparatus of claim 2 , wherein the label includes a plurality of colors claim 2 , each color associated with a level of potency the portion of4. The apparatus of claim 1 , wherein the machine-readable identification indicium includes a barcode providing a unique identifier.5. A computer-related method claim 1 , comprising:reading, via a tracking application executed on a mobile computing device, information from a label affixed to a therapeutic substance, the information associated with the therapeutic substance; andtransmitting the information to a database stored on a remote computing device.6cannabis. A labeling system for preventing accidental and/or undesirable ingestion of infused products claim 1 , comprising:{'i': 'cannabis', 'a infused product;'}{'i': cannabis', 'cannabis, 'a label including a barcode providing a unique identifier, a label indicia representing -related specifics of the infused product, the label indicia associated with the unique identifier; and'}a database providing ...

Подробнее
Номер записи: 54
02-04-2020 дата публикации

IMPROVED FIBRINOGEN-BASED TISSUE ADHESIVE PATCH

Номер: US20200101024A1
Автор: Cohen Eran, LAUB Orgad, SCHWARTZ Yotam
Принадлежит:

An improved fibrinogen-based tissue sealing patch having a degradation time of less than two weeks is disclosed. The patch comprises a polyethylene glycol-caprolactone-lactide (PEG-CL-LA) triblock copolymer film in which the PEG-CL-LA units are preferably connected by urethane linkages and into a surface of which a fibrinogen-based sealant comprising less than 8 mg/cmfibrinogen and less than 10 IU/cmthrombin has been incorporated. In preferred embodiments, the polymer film comprises PEG having a molecular weight of between 3000 and 3500 and a CL:LA:PEG ratio of 34:2:1. Methods of production and use of the patch are also disclosed. 1. A fibrinogen-based tissue adhesive patch , wherein said adhesive patch comprises:a backing made from a film made of a biocompatible polyethylene glycol-caprolactone-lactide (PEG-CL-LA) triblock copolymer (PECALA) comprising PEG having a molecular weight of between 3000 and 3500 and a CL:LA ratio of 34:2; and,{'sup': 2', '2, 'a fibrinogen sealant comprising less than 8 mg/cmfibrinogen and less than 20 IU/cmthrombin incorporated into said biocompatible polymer backing;'}wherein:said PECALA comprises PEG-CL-LA units connected by isocyanate linkages;said fibrinogen sealant is incorporated into a surface of said biocompatible polymer backing; and,said adhesive patch does not include any interpenetrating polymer network; any mesh or woven component; any non-woven fabric; or any material made by methods of paper-making technology.2. The fibrinogen-based tissue adhesive patch according to claim 1 , wherein said backing is characterized by at least one physical characteristic selected from the group consisting of:a Young's Modulus of between 50 MPa and 200 MPa;a tensile strength of between 5 MPa and 15 MPa;a melting point of between 45° C. and 52° C.;a water uptake of between 30% and 50%; and,a breakdown time in water (half-life) of between 15 days and 30 days.3. The fibrinogen-based tissue adhesive patch according to claim 1 , wherein said ...

Подробнее
Номер записи: 55
10-07-2014 дата публикации

HYDROGEL COMPRISING CATECHOL GROUP-COUPLED CHITOSAN OR POLYAMINE AND POLOXAMER COMPRISING THIOL GROUP COUPLED TO END THEREOF, PREPARATION METHOD THEREOF, AND HEMOSTAT USING SAME

Номер: US20140193360A1
Автор: Lee Haeshin, Lee Moon Sue, RYU Ji Hyun
Принадлежит: Innotherapy Inc.

The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same. 1. A hydrogel composition comprising: (i) a catechol group-coupled chitosan or polyamine; and (ii) a polaxamer thiol group-coupled to the end thereof.2. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 10 claim 1 ,000 Da˜1 claim 1 ,000 claim 1 ,000 Da.3. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 50 claim 1 ,000 Da˜200 claim 1 ,000 Da.5. The hydrogel composition of claim 1 , wherein said catechol group-coupled polyamine is any one or more selected from the group consisting of ethylene diamine claim 1 , 1 claim 1 ,3-diaminopropane claim 1 , hexamethylenediamine claim 1 , tetraethylmethylenediamine claim 1 , putrescine claim 1 , cadaverine claim 1 , spermidine claim 1 , spermine claim 1 , linear polyethyleneimine claim 1 , branched polyethyleneimine claim 1 , and ε-poly-L-lysine.6. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a 1-20 mole % of catechol group content to the chitosan or polyamine.7. The hydrogel composition of claim 1 , wherein said polaxamer thiol group-coupled to the end thereof has a 50-100 mole % of thiol group content to the polaxamer.8. The hydrogel composition of claim 1 , wherein the hydrogel composition further comprises a therapeutic drug.9. The hydrogel composition of claim 8 , wherein the therapeutic drug is any one or more selected from the group consisting of human growth hormones ...

Подробнее
Номер записи: 56
26-04-2018 дата публикации

BIOADHESIVE CHITOSAN GEL FOR CONTROLLING BLEEDING AND FOR PROMOTING HEALING WITH SCAR REDUCTION WITHOUT OBSCURING OR INTERFERING WITH ACCESS TO A SURGICAL FIELD

Номер: US20180110897A1
Автор: Bush Maggie, KUHN Sam, McCarthy Simon
Принадлежит:

An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt. 1. An aqueous gel comprising:water in an amount greater than about 80% (w/w);chitosan in an amount of about 2% to about 12% (w/w);an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w);a rheology modifying agent in an amount of about 0.5% to about 5% (w/w);an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w);an alcohol in an amount of about 0.2% to about 10% (w/w); anda multi-valent salt in an amount of about 0.1% to about 0.5% (w/w).2. The aqueous gel of claim 1 , wherein the aqueous gel is at least one of clear and transparent.3. The aqueous gel of claim 1 , wherein the aqueous gel is stable for a period up to three years at about 23° C.4. The aqueous gel of claim 1 , further comprising a plasticizer in an amount up to about 5% (w/w).5. The aqueous gel of claim 1 , wherein the aqueous gel is bioabsorbable and the chitosan has a percent degree of deacetylation between 20% and 40%.6. The aqueous gel of claim 1 , wherein the aqueous gel is removable and the chitosan has a percent degree of deacetylation greater than about 78%.7. The aqueous gel of claim 1 , wherein at least one of: the monofunctional organic ...

Подробнее
Номер записи: 57
18-04-2019 дата публикации

IMAGEABLE POLYMERS

Номер: US20190111159A1
Автор: Ashrafi Koorosh, DREHER Matthew R., HOHN Stephane, LEWIS Andrew Lennard, TANG Yiqing, Willis Sean Leo
Принадлежит:

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system 137.-. (canceled)38. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;the PVA backbone further comprising 1,3-diol groups acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.39. Hydrogel polymer microspheres according to wherein the pendant chains comprising cross-linkable ethylenically unsaturated functional groups are attached to the 1 claim 38 ,3-diol groups of the PVA backbone via cyclic acetal linkages.40. Hydrogel polymer microspheres according to wherein the vinylic co-monomer is 2-acrylamido-2-methylpropanesulfonic acid.41. Hydrogel polymer microspheres according to wherein the ethylenically unsaturated functional groups are acrylate groups.42. Hydrogel polymer microspheres according to wherein the radiopaque species comprises an iodinated phenyl group.44. Hydrogel polymer microspheres according to wherein claim 43 , Z is (i) a methylene or ethylene group or is (ii) a group —(CH)—O—(CH)— wherein q is 0 claim 43 , 1 or 2 and p is 1 or 2 or is (iii) absent.45. Hydrogel polymer microspheres according to wherein claim 43 , Z is —CHO— claim 43 , —(CH)O— claim 43 , —CHOCH— claim 43 , —(CH)O(CH)— or is absent.46. Hydrogel polymer microspheres according to wherein Hal is 3 or 4 iodines.47. Hydrogel polymer microspheres according to wherein Hal is 2 claim 43 ,3 claim 43 ,5 triiodo claim 43 , 2 ...

Подробнее
Номер записи: 58
05-05-2016 дата публикации

Hydrogel Pressure Sealant System

Номер: US20160120528A1
Автор: Abtin Fereidoun
Принадлежит:

The present invention includes devices, systems, and methods for sealing a defect in body tissue. For example, the present invention includes a device for preventing leakage of air and other gases from the lung during and after lung biopsy. The device delivers a hydrogel composition which forms an air-tight sealant. In certain embodiments, the device simultaneously delivers one or more therapeutic agents, such as lidocaine, to the treatment area. 1. A device for sealing a tissue defect in a body tissue of a subject , wherein the device comprises:a first barrel and a first plunger engaged with the proximal end of the first barrel, thereby forming a first chamber within the first barrel, wherein the first chamber houses a first component of a hydrogel;a second barrel and a second plunger engaged with the proximal end of the second barrel, thereby forming a second chamber within the second barrel chamber, and wherein the second chamber houses a second component of a hydrogel; andat least one port connecting the first chamber and second chamber;wherein the contents of the first chamber and second chamber are temporarily isolated to prevent contact of the first component and second component prior to mixing.2. The device of claim 1 , wherein the port is configured for control by a user to allow communication between the first chamber and second chamber claim 1 , thereby allowing contact of the first component and second component to form a hydrogel solution.3. The device of claim 1 , further comprising at least one outlet positioned on at least one of the first chamber and second chamber.4. The device of claim 1 , wherein the outlet is configured to mate with a delivery instrument claim 1 , selected from the group consisting of a needle and a catheter.5. The device of claim 1 , wherein at least one of the first component and second component comprises one or more therapeutic agents.6. The device of claim 1 , wherein the one or more therapeutic agents comprise one or more ...

Подробнее
Номер записи: 59
05-05-2016 дата публикации

SINGLE SOLUTION of Gel-LIKE FIBRIN HEMOSTAT

Номер: US20160121017A1
Автор: Falus George
Принадлежит: Biomedica Management Corp

The present invention trademarked ClotGel© is a fibrin II-based hemostat made of two components that are mixed into a single syringe to be delivered as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its cross-linking technology generates an adhesive stable fibrin clot required for hemostasis. The agent consists of a cross-linked gelatin that is homogenized in a solution of fibrin monomer in acetic acid, which is reconstituted before use from a lyophilized fibrin monomer. When both components are mixed into a syringe they produce a viscous gel-like composition that is polymerized and stabilized when in contact with blood. The attachment properties of the composition, as well as the rapid formation of a fibrin clot, ensures that a strong stable blood clot is formed over a bleeding wound within 2 minutes of application. 1. A composition for the control of bleeding in humans with or without compression comprising:a) lyophilized desAB fibrin monomer (fibrin II)b) acetic acid solution for reconstitution of lyophilized fibrin monomerc) cross-linked gelatin2. The composition as claimed in wherein the acetic acid solution has a pH of 3.4-3.5.3. The composition as claimed in wherein the fibrin monomer in acid solution is mixed 5:1 with dihydrate trehalose USP-NF previous to lyophilization.4. The composition as claimed in wherein the mixture of fibrin monomer with trehalose is lyophilized in particles of 50 μm to 200 μm containing at least 20% fibrin II monomer.5. The composition as claimed in wherein the lyophilized fibrin monomer can be reconstituted in less than two minutes by dissolving the fibrin microparticles it in a solution of acetic acid at pH 3.56. the composition as claimed in wherein the fibrin monomer can be reconstituted in acetic acid solution at a concentration ranging from 20 mg/mL to 40 mg/ml.7. ...

Подробнее
Номер записи: 60
09-06-2022 дата публикации

ULTRASOUND DRIVEN MXENE HYDROGEL ELECTRICAL POWER GENERATOR AND METHOD

Номер: US20220181891A1
Автор: ALSHAREEF Husam Niman, LEE Kang Hyuck, ZHANG Yizhou
Принадлежит:

An electrical power generator includes an M-gel layer that includes MXene and a hydrogel, first and second flexible layers that sandwich the M-gel layer so that the M-gel layer is sealed from an ambient, and a single terminal electrically connected to the M-gel layer. The M-gel layer is configured to transform acoustic energy into electrical energy. 1. An electrical power generator comprising:an M-gel layer that includes MXene and a hydrogel;first and second flexible layers that sandwich the M-gel layer so that the M-gel layer is sealed from an ambient; anda single terminal electrically connected to the M-gel layer,wherein the M-gel layer is configured to transform acoustic energy into electrical energy.2. The electrical power generator of claim 1 , wherein the M-gel layer transforms ultrasound energy.3. The electrical power generator of claim 1 , wherein the first and second flexible layers include a polymer.4. The electrical power generator of claim 1 , wherein a thickness of the M-gel layer is smaller than 1 cm.5. The electrical power generator of claim 1 , wherein a thickness of the M-gel layer is about 1 mm.6. The electrical power generator of claim 5 , wherein a thickness of each of the first and second flexible layers is about 1 mm.7. The electrical power generator of claim 1 , wherein each of the first and second flexible layers are directly in contact with the M-gel layer.8. The electrical power generator of claim 1 , further comprising:first and second positive charged layers,wherein the first positive charged layer is located between the M-gel layer and the first flexible layer, andwherein the second positive charged layer is located between the M-gel layer and the second flexible layer.9. The electrical power generator of claim 8 , wherein the first and second positive charged layers include nylon.10. The electrical power generator of claim 8 , wherein the first and second flexible layers are negative charged layers.11. The electrical power generator of ...

Подробнее
Номер записи: 61
25-08-2022 дата публикации

SYSTEMS, DEVICES AND METHODS FOR DISPENSING BIOCOMPATIBLE REACTIVE FORMULATIONS AND CONTROLLING CROSS-LINKING OF THE REACTIVE COMPONENTS OF THE BIOCOMPATIBLE REACTIVE FORMULATIONS

Номер: US20220265938A1
Автор: Dhanaraj Sridevi, Ghodbane Salim, Guo Jianxin
Принадлежит:

A system for dispensing a biocompatible reactive formulation includes a first chamber containing a first fluid having a first reactive component, a second chamber containing a second fluid having a second reactive component, and a third chamber containing a third fluid. A spray tip assembly is configured for spraying a final mixture of the first, second and third fluids. The spray tip assembly has a spray tip housing, a mixing element disposed within the spray tip housing, a mixing chamber located between the mixing element and an inner surface of the spray tip housing. The mixing element has a proximal end adjacent the proximal end of the spray tip housing and a distal end adjacent the distal end of the spray tip housing, a third fluid inlet opening at the proximal end of the mixing element, and one or more third fluid exit openings formed in the outer surface of the mixing element that are in fluid communication with the third fluid inlet opening and that extend laterally to the outer surface of the mixing element for being in fluid communication with the mixing chamber. A fluid connector is secured to the proximal end of the spray tip housing and opposes the proximal end of the mixing element. The fluid connector has first and second fluid channels in fluid communication with the mixing chamber, and a third fluid channel in fluid communication with the third fluid inlet opening of the mixing element. A pump assembly is coupled with the first, second and third chambers for simultaneously forcing the first, second and third fluids to flow through the first, second and third fluid channels of the fluid connector and into the proximal end of the spray tip housing. 1. A system for dispensing a biocompatible reactive formulation comprising:a spray tip housing having a proximal end, a distal end, an outer wall that extends from said proximal end to said distal end of said spray tip housing, and an elongated conduit surrounded by said outer wall that extends from said ...

Подробнее
Номер записи: 62
27-05-2021 дата публикации

HEMOSTATIC EFFICACY OF A NANOSTRUCTURED FIBRIN AGAROSE HYDROGEL

Номер: US20210154352A1
Автор: CAMPOS CUERVA Rafael, CEPEDA FRANCO Carmen, FERNANDEZ MUÑOZ Beatriz, GÓMEZ BRAVO Miguel Angel, MUNTANE RELAT Jordi
Принадлежит:

The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application. 1. A composition for use in the control of bleeding with or without compression , wherein the composition comprises nanostructured fibrin and agarose hydrogels , preferably type VII agarose hydrogels , (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels , preferably type VII agarose hydrogels , (FAH).2. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as biological tissue sealants and/or hemostats.3. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as an adjunct to hemostasis in laparotomy or laparoscopic surgery claim 1 , in orthopedic surgery claim 1 , trauma (spleen laceration or hepatic surgery) claim 1 , or large-bed wounds.4. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as adjunct and/or primary treatment in moderate bleeding.5. The composition for use according to any of to claim 1 , wherein the composition is cellularized nanostructured fibrin and agarose hydrogels claim 1 , preferably type VII agarose hydrogels claim 1 , (c-NFAH).6. The composition for use according to any of to claim 1 , ...

Подробнее
Номер записи: 63
14-05-2015 дата публикации

RADIATION STERILIZATION-RESISTANT PROTEIN COMPOSITION

Номер: US20150132279A1
Автор: Akiyama Yusuke, Fujinaga Kentaro, HIRASHIMA MASAKI, HONDA Susumu, Ishiwari Ayumi, Kageyama Yukako, Kaneko Hiroaki, Katou Souichirou, Kimura Yukiko, Satake Makoto, YAMAGUCHI Ayuko
Принадлежит:

A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization. 1. A protein composition which comprises a mixture of glycine , phenylalanine and histidine and/or a cellulose ether derivative as an additive.2. The protein composition according to claim 1 , wherein the additive is a cellulose ether derivative and a protein is contained in the cellulose ether derivative.3. The protein composition according to claim 1 , wherein the additive is a mixture of glycine claim 1 , phenylalanine and histidine.4. The protein composition according to claim 1 , wherein the additive consists of a mixture of glycine claim 1 , phenylalanine and histidine and a cellulose ether derivative claim 1 , and a protein is contained in the cellulose ether derivative.5. The protein composition according to claim 1 , wherein the cellulose ether derivative is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose and mixtures thereof.6. The protein composition according to claim 1 , wherein the cellulose ether derivative is selected from the group consisting of hydroxypropyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose and mixtures thereof.7. The protein composition according to claim 1 , wherein the cellulose ether derivative is hydroxypropyl cellulose.8. The protein composition according to claim 1 , wherein the protein is selected from the group consisting of enzymes claim 1 , transport proteins claim 1 , muscle proteins claim 1 , defense proteins claim 1 , toxin proteins claim 1 , protein hormones claim 1 , storage proteins claim 1 , structural proteins claim 1 , growth factors and mixtures thereof.9. The protein composition according to claim 1 , wherein the protein is fibrinogen.10. The ...

Подробнее
Номер записи: 64
12-05-2016 дата публикации

MULTI-COMPONENT ADHESIVE FOR PRODUCING AN ADHESIVE HYDROGEL

Номер: US20160130484A1
Автор: Bargel Hendrik, Kozielec Maria, Rischka Klaus, Sader Robert
Принадлежит:

The present invention primarily relates to a multicomponent adhesive for producing an adhesive hydrogel, comprising the compound defined below of the formula (I) and one, two, three, four or more further constituents. The invention further relates to the use of said multicomponent adhesive and corresponding methods for gluing two surfaces together. The present invention further relates to a method for producing a corresponding adhesive hydrogel. The invention also relates to a kit comprising a corresponding multicomponent adhesive and one or more further constituents. The invention also relates to articles which comprise a multicomponent adhesive according to the invention or an adhesive hydrogel produced therefrom. 2. The multicomponent adhesive as claimed in claim 1 , further comprising at least one of{'sub': 'B', 'd) a buffer consisting of a buffer acid and a corresponding buffer base, where the pKof the buffer base is not less than 2,'}and{'sub': 'B', 'e) one or more bases with a pK<1.'}3. The multicomponent adhesive as claimed in claim 1 , wherein the first compound of the formula (I) contains at least one cysteine unit.5. The multicomponent adhesive as claimed in claim 1 , wherein at least one of(i) the linker L of the first compound of the formula (I) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms,(ii) the linker L′ in the structural unit B-L′-Y (II) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms,and(iii) the linker L″ in the structural unit B′-L″-Z′ (III) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms.6. The multicomponent adhesive as claimed in claim 1 , wherein the linker L in the first compound of the formula (I) contains at least one structural ...

Подробнее
Номер записи: 65
30-04-2020 дата публикации

BIOADHESIVE HYDROGELS

Номер: US20200129660A1
Автор: Alsberg Eben, Jeon Oju
Принадлежит:

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer. 1. A bioadhesive comprising: a crosslinked biodegradable hydrogel that includes a plurality of oxidized , acrylated or methacrylated , natural polymer macromers crosslinked with a plurality of branched poly(ethylene glycol) macromers.2. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers include a plurality of aldehyde groups that are crosslinked with the branched poly(ethylene glycol) macromers.3. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers are polysaccharides claim 1 , which are oxidized so that about 1% to about 50% of the saccharide units therein are converted to aldehyde saccharide units.4. The bioadhesive of claim 1 , wherein acrylate or methacrylate groups of the natural polymer macromers are crosslinked so that the hydrogel is dual crosslinked.5. The bioadhesive of claim 1 , the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers comprising oxidized claim 1 , acrylated or methacrylated claim 1 , alginates.6. The bioadhesive of claim 1 , wherein the poly(ethylene glycol) macromers are poly(ethylene glycol) amine macromers.7. The bioadhesive of claim 6 , wherein the poly(ethylene glycol) amine macromers are n-arm poly(ethylene glycol) amines claim 6 , where n is an integer greater than 1.8. The bioadhesive of claim 1 , wherein the hydrogel is cytocompatible and claim 1 , upon degradation claim 1 , produces substantially non-toxic products.9. The bioadhesive of claim 1 , wherein the hydrogel is photocrosslinked.10. A bioadhesive comprising: a dual crosslinked biodegradable hydrogel that includes a plurality of oxidized claim 1 , acrylated or methacrylated claim 1 , polysaccharide macromers crosslinked with a plurality of branched poly(ethylene ...

Подробнее
Номер записи: 66
16-05-2019 дата публикации

MEDICAL HYDROGEL COMPOSITION, AND MEDICAL HYDROGEL, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Номер: US20190142994A1
Автор: Deng Kunxue, LIN Limin, Ma Cheng, Yang Yaya, Yuan Yuyu
Принадлежит: Medprin Regenerative Medical Technologies Co., Ltd.

A medical hydrogel composition, a medical hydrogel, a preparation method therefore and an application thereof, and a medical hydrogel kit. The medical hydrogel composition comprises a first component and a second component; the first component comprises polylysine and polyethylene imine; the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, and 4-arm-polyethylene glycol-succinimidyl carbonate; the degree of polymerization of the polylysine is 20 or more. The medical hydrogel is formed by reacting the first component with the second component of the medical hydrogel composition. The medical hydrogel kit comprises the medical hydrogel composition and a buffer solution used for dissolving the components of the medical hydrogel composition. The medical hydrogel has a degree of swelling of −10%-50%, and can be applied in narrow parts where cranial, spinal, and peripheral nerves are densely distributed. 1. A medical hydrogel composition , wherein the medical hydrogel composition comprises a first component and a second component , the first component comprises polylysine and polyethylene imine , the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate , 4-arm-polyethylene glycol-succinimidyl succinate , and 4-arm-polyethylene glycol-succinimidyl carbonate , and wherein the polylysine has a degree of polymerization of 20 or more , preferably 25 to 35.2. The medical hydrogel composition according to claim 1 , wherein in the first component claim 1 , a mass ratio of the polylysine to the polyethylene imine is 0.1 to 10.3. The medical hydrogel composition according to claim 1 , wherein the polylysine is ε-polylysine and/or poly-L-lysine.4. The medical hydrogel composition according to claim 3 , wherein the weight average molecular weight of the ε-polylysine is 3000 to 5000 Da.5. The medical hydrogel composition according to claim 3 , wherein the ...

Подробнее
Номер записи: 67
07-05-2020 дата публикации

BIODEGRADABLE SEALANT AND USE OF A BIODEGRADABLE SEALANT IN MANUFACTURE OF AN AGENT FOR BIOLOGICAL TISSUE ADHESION OR REPAIR

Номер: US20200139003A1
Автор: CHEN Sen-Lu, Lee Yi-Hsuan, LIN Jian-Wei, LIOU Yu-Bing, Shen Hsin-Hsin, SHEN Ying-Wen, WANG Yu-Chi, YANG Ming-Chia, Yu Wei-Lin
Принадлежит: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

A biodegradable sealant includes: a polyethylene glycol derivative; a photoinitiator; and a solvent, wherein the content of the polyethylene glycol derivative is about 10-75 wt % in the biodegradable sealant. The polyethylene glycol derivative is obtained by a substitution reaction, and in the substitution reaction, the polyethylene glycol is modified with methacrylic anhydride. 1. A biodegradable sealant , comprisinga polyethylene glycol derivative, wherein the polyethylene glycol derivative is obtained through a substitution reaction, and in the substitution reaction, polyethylene glycol is modified with methacrylic anhydride;a photoinitiator; anda solvent,wherein the content of the polyethylene glycol derivative in the biodegradable sealant is about 10-75 wt %.2. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500-35000.3. The biodegradable sealant as claimed in claim 1 , the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500 claim 1 , 8000 or 35000.4. The biodegradable sealant as claimed in claim 1 , wherein the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:0.01-10.5. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500 claim 1 , and the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:1-10.6. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 8000 claim 1 , and the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:0.05-1.5.7. The ...

Подробнее
Номер записи: 68
09-06-2016 дата публикации

SELF-ASSEMBLING BIOMIMETIC HYDROGELS HAVING BIOADHESIVE PROPERTIES

Номер: US20160158406A1
Автор: IFTODE Cristina, JOHNSON Bryan, KADLOWEC Jennifer, KUBINSKI Pamela, TULENKO Thomas N., VERNENGO Andrea Jennifer, WILTSEY Craig
Принадлежит: ROWAN UNIVERSITY

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101.-. (canceled)103. The method of claim 102 , wherein said delivering is to a human disc in vivo.104. The method of claim 102 , wherein the TD polymer is selected from the group consisting of poly(ethylene oxides) (PEOs) claim 102 , poly(propylene oxides) (PPOs) claim 102 , copolymers of PEO and poly(lactic acid) (PLA) claim 102 , poly(n-isopropyl acrylamides) (PNIPAAms) claim 102 , mixtures of the foregoing claim 102 , and copolymers of the foregoing.105. The method of claim 102 , wherein the TD polymer is covalently linked with an ECM polymer.106. The method of claim 105 , wherein the ECM polymer is the same polymer as the polymeric component.108. The method of claim 107 , wherein said composition further comprises: ...

Подробнее
Номер записи: 69
22-09-2022 дата публикации

NOVEL GLUE FOR EMBOLIZATION OF LYMPHATIC LEAKAGE

Номер: US20220296772A1
Автор: BAYAT Niki, Dabiri Ali, Kassab Ghassan S., Menefee Roby
Принадлежит:

A novel glue for embolization of lymphatic leakage. An optimized lymphatic embolization agent (LEA) as described herein comprises a NAM hydrogel and tantalum at a mixture of at or about 1:3 tantalum to NAM hydrogel, wherein said LEA is radiopaque. 1. An optimized lymphatic embolization agent (LEA) , comprising a NAM hydrogel and tantalum at a mixture of at or about 1:3 tantalum to NAM hydrogel , wherein said LEA is radiopaque.2. The LEA of claim 1 , wherein the NAM hydrogel comprises NAm.3. The LEA of claim 2 , wherein the NAmis produced by dissolving NIPAM claim 2 , Am and 2 claim 2 ,2′ azobisisobutryonitrile in tetrahydrofuran claim 2 , degassing under elevated temperature claim 2 , and isolating the resultant product claim 2 , wherein the resultant product comprises NAm.4. The LEA of claim 2 , wherein the NAmis synthesized by free radical polymerization.5. The LEA of claim 1 , configured for injection into a mammalian subject through a 3 Fr catheter.6. The LEA of claim 1 , configured to solidify within 45 seconds at a temperature of 37° C.7. The LEA of claim 1 , configured to solidify within 30 seconds at a temperature of 37° C.8. The LEA of claim 1 , configured to solidify within 15 seconds at a temperature of 37° C.9. The LEA of claim 1 , configured to resist displacement under 800 mmHg of pressure after 60 seconds at 37° C.10. The LEA of claim 1 , configured as a lymphatic sealant.11. A method of occluding a lymphatic vessel claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'introducing the LEA of into a mammalian patient at or near a lymphatic vessel to occlude said vessel.'}12. The method of claim 11 , wherein the step of introducing comprises introducing at or about 3 ml of the LEA so that at or about 1 ml of solid glue forms at or about 37° C.13. The method of claim 11 , wherein the solid glue resists migration.14. A method of treating lymphatic leakage claim 1 , comprising introducing the LEA of into a mammalian patient at or near a ...

Подробнее
Номер записи: 70
08-06-2017 дата публикации

THROMBIN MICROCAPSULES, PREPARATION AND USES THEREOF

Номер: US20170157222A1
Автор: Gershonovitch Assaf, ILAN Erez, Kaufman Rivka
Принадлежит:

Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof. 1. Spray-dried thrombin powder comprising microcapsules , the powder comprising:thrombin, a carrier protein and a carbohydrate, wherein the ratio of thrombin:carrier protein is about 0.85 IU:1 mg to 66,875 IU:1 mg, and wherein the ratio of thrombin:carbohydrate is 0.75 IU:1 mg to 26,750 IU:1 mg.2. The spray-dried thrombin powder of claim 1 , wherein the ratio of thrombin:carrier protein is from about 110 IU:1 mg to about 285 IU:1 mg claim 1 , optionally from about 129 IU:1 mg to about 219 IU:1 mg.3. The spray-dried thrombin powder of claim 1 , wherein the carrier protein comprises albumin.4. The spray-dried thrombin powder of claim 1 , wherein the carbohydrate is a sugar alcohol or a saccharide.5. The spray-dried thrombin powder of claim 1 , wherein the carrier protein is albumin and the carbohydrate is mannitol claim 1 , wherein the ratio of thrombin:albumin is about 0.85 IU:1 mg to 66 claim 1 ,875 IU:1 mg claim 1 , and wherein the ratio of thrombin:mannitol is 0.75 IU:1 mg to 26 claim 1 ,750 IU:1 mg.6. The spray-dried thrombin powder of claim 5 , wherein the ratio of thrombin:albumin is from about 110 IU:1 mg to about 285 IU:1 mg claim 5 , optionally from about 129 IU:1 mg to about 219 IU:1 mg.7. The spray-dried thrombin powder of claim 5 , wherein the ratio of thrombin:mannitol is from about 40 IU:1 mg to about 64 IU:1 mg.8. The spray-dried thrombin powder of claim 1 , comprising from about 0.001% to about 5% w/w thrombin.9. The spray-dried thrombin powder of claim 1 , comprising less than about 3% w/w water.10. The spray-dried thrombin powder of claim 1 , having a particle size distribution of D50 of from about 5 to about 13 μm and D90 of from about 15 to about 25 μm.11. An aqueous composition suitable for use in preparing thrombin microcapsules claim 1 , the aqueous composition comprising:thrombin, a carrier protein and a carbohydrate, wherein the ratio ...

Подробнее
Номер записи: 71
08-06-2017 дата публикации

IN SITU SOLIDIFYING COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF

Номер: US20170157285A1
Автор: Stewart Russell J.
Принадлежит: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications. 1. A method for producing an adhesive solid or gel in a subject in situ comprising introducing into the subject a fluid complex coacervate comprising at least one polycation , at least one polyanion , and a monovalent salt , wherein the concentration of the monovalent salt in the complex coacervate is greater than the concentration of the monovalent salt in the subject , wherein upon introduction of the fluid complex coacervate into the subject the adhesive solid or gel is produced in situ.2. The method of for reducing or inhibiting blood flow in a blood vessel of the subject comprising introducing into the vessel the fluid complex coacervate claim 1 , wherein the adhesive solid or gel produced from the fluid complex coacervate creates an artificial embolus within the vessel.3. The method of claim 2 , wherein the method reduces or inhibits blood flow to a tumor claim 2 , an aneurysm claim 2 , a varicose vein claim 2 , an arteriovenous malformation claim 2 , or a bleeding wound.4. The method of claim 2 , wherein the fluid complex coacervate further comprises an embolic agent comprising ...

Подробнее
Номер записи: 72
28-08-2014 дата публикации

SELF HEALING HYDROGELS

Номер: US20140243428A1
Автор: Phadke Ameya, Varghese Shyni
Принадлежит:

The disclosure provides for self-healing hydrogels, complex structures made therefrom, and use thereof, including use of the hydrogels as self-healing coatings, self-healing sealants, tissue adhesives, and drug carriers. 4. The self-healing hydrogel of claim 1 , wherein the one or more cross-linking precursors are selected from the group consisting of optionally substituted N claim 1 ,N′-methylenebisacrylamide claim 1 , 1 claim 1 ,4-cyclohexanedimethanol divinyl ether claim 1 , ethylene glycol diacrylate claim 1 , ethylene glycol dimethacrylate claim 1 , divinylbenzene claim 1 , 4 claim 1 ,4′-methylenebis(cyclohexyl isocyanate) claim 1 , 1 claim 1 ,6-hexanediol diacrylate claim 1 , 1 claim 1 ,4-phenylenediacryloyl chloride claim 1 , and tetra(ethylene glycol) diacrylate.5. The self-healing hydrogel of claim 1 , wherein the cross linking precursor is N claim 1 ,N′-methylenebisacrylamide.6. The self-healing hydrogel of claim 1 , wherein the hydrogel comprises 0.01% to 1% percent of cross-linking precursors.7. The self-healing hydrogel of claim 1 , wherein the hydrogel comprises about 0.1% of cross-linking precursors.8. The self-healing hydrogel of claim 1 , wherein the pendant side chain can form at least two hydrogen bonds to one or more additional pendant side chains.9. The self-healing hydrogel of claim 8 , wherein the hydrogen bonds can form when the hydrogel is exposed to a pH of less than or equal to 5.10. The self-healing hydrogel of claim 8 , wherein the hydrogen bonds break when the hydrogel is exposed to a pH of greater than or equal to 9.11. A structure comprising at least two or more hydrogels of which are linked together by hydrogen bonding.12. A self-healing coating comprising a hydrogel of .13. A self-healing sealant comprising a hydrogel of .14. A tissue adhesive comprising a hydrogel of .15. The tissue adhesive of claim 14 , wherein the tissue adhesive is used as a mucoadhesive for gastric tissue.16. A drug carrier comprising a hydrogel of .17. The ...

Подробнее
Номер записи: 73
29-09-2022 дата публикации

THERMOSENSITIVE BIO-ADHESIVE HYDROGEL FOR REMOVAL OF URETERAL AND RENAL STONES

Номер: US20220304766A1
Автор: Clayman Ralph V., Jiang Pengbo, Schoenberg Mark, Tsipori Omer
Принадлежит:

Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatically improved the efficiency and effectiveness of stone clearance compared to conventional techniques while providing protection to the urothelium from potentially damaging temperature spikes. 2. The method of claim 1 , wherein the thermosensitive bio-adhesive hydrogel protects urothelium of the subject from internal thermal damage or disruption resultant from the lithotripsy procedure.3. The method of claim 1 , wherein the stone clearance is at least 90%-99.9% claim 1 , inclusive.4. The method of claim 1 , wherein the method inhibits renal backflow claim 1 , selected from the group consisting of pyelovenous claim 1 , pyelosinus claim 1 , and pyelolymphatic backflow.5. The method of claim 1 , wherein the lithotripsy procedure comprises exposing the patient to a high-power laser capable of reaching 200-500 watts.6. The method of claim 1 , wherein the lithotripsy is selected from the group consisting of ultrasonic lithotripsy claim 1 , holmium laser lithotripsy (YAG) claim 1 , thulium fiber laser lithotripsy claim 1 , super pulse thulium fiber laser lithotripsy claim 1 , pneumatic claim 1 , and electrohydraulic.7. The method of claim 2 , wherein the hydrogel partially or completely protects the urothelium from thermal damage.8. The method of claim 7 , wherein the hydrogel inhibits peak intra-calyceal or intraureteral temperature of 38° C. during the lithotripsy procedure.9. The method of claim 1 , wherein the tri block copolymer having an ABA formula is EPO/PPO/EPO block copolymer.10. The method of claim 9 , wherein the tri block copolymer having an ABA formula has an average molecular weight 1100-20000 Da inclusive.11. The method of claim 1 , wherein the tri block copolymer having ABA formula is Poloxamer 407 or Poloxamer 338.12. The ...

Подробнее
Номер записи: 74
21-06-2018 дата публикации

METHOD OF MANUFACTURING A SEASONING BAG

Номер: US20180170637A1
Автор: Carroll Chris
Принадлежит:

In a method for manufacturing a seasoning bag, an edible adhesive is applied to a panel of a bag in a pattern of spaced apart lines. A granular seasoning is applied to the panel of the bag such that the granular seasoning adheres to the edible adhesive pattern to produce a seasoning layer having a pattern substantially the same as the edible adhesive pattern. 1. A method for manufacturing a seasoning bag , comprising:applying an edible adhesive to a panel of a bag in a pattern of spaced apart lines; andapplying a granular seasoning to the panel of the bag such that the granular seasoning adheres to the edible adhesive pattern to produce a seasoning layer having a pattern substantially the same as the edible adhesive pattern.2. The method of claim 1 , wherein the edible adhesive is applied in an amount ranging from about 25 mg per square inch to about 100 mg per square inch.3. The method of claim 1 , wherein the granular seasoning is applied in an amount ranging from about 25 mg per square inch to about 450 mg per square inch.4. The method of wherein the thickness of the edible adhesive ranges from about 3 mil to about 18 mil and the thickness of the seasoning ranges from about 3 mil to about 18 mil.5. The method of claim 1 , wherein the granular seasoning is configured to form a liquid marinate when combined with water added to the seasoning bag.6. The method of claim 1 , wherein the granular seasoning is configured to form a broth when combined with water added to the seasoning bag.7. The method of claim 1 , wherein the granular seasoning is configured to form a sauce when combined with water added to the seasoning bag.8. The method of wherein the bag is vacuum sealable.9. The method of wherein the bag is at least one of an ovenable bag claim 1 , a bailable bag claim 1 , a slow cooking bag claim 1 , or a microwavable bag.10. The method of claim 1 , wherein the granular seasoning includes at least one of a coloring additive claim 1 , a nutrient claim 1 , an ...

Подробнее
Номер записи: 75
22-06-2017 дата публикации

WOUND CLOSURE COMPOSITIONS AND METHOD

Номер: US20170173209A1
Автор: Russo Joseph D.
Принадлежит: Rousseau Research, Inc.

A medical adhesive that bonds well to human tissue while curing in a fast, controllable mariner. In a preferred form, the medical adhesive includes an oligomer, a hydrogel and/or water soluble polymer and a photoinitiator. Preferred oligomers include epoxides, urethanes, polyethers, polyester or a combination thereof. Hydrogels and water soluble polymers aid adhesion to moist surfaces, such as skin tissue, because they are hydrophilic and biodegradable, Preferred hydrogels include polymer hydrogels (PHGs). Suitable water soluble polymers include polyethylene oxide) (PEO) and poly-2-oxazoline. The photoinitiator is used to obtain fast, controllable curing of the adhesive compound. Curing takes place on demand when ultraviolet (UV) light is applied to the medical adhesive. To increase adhesion as well as to control flexibility and toughness, the medical adhesive may also include one or more monomers. Suitable monomers include acrylates and vinyls. 1. An adhesive composition comprising:an oligomer:a hydrogel and/or water soluble polymer; and,a photoinitiatorwherein said adhesive composition will cure when it is exposed to ultraviolet light.2. The adhesive composition of wherein there is curing on demand claim 1 ,3. The adhesive composition of wherein said oligomer is selected from the group consisting of epoxides claim 1 , urethanes claim 1 , polyethers claim 1 , polyesters or a combination thereof.4. The adhesive composition of further comprising a chromophore claim 1 , a fluorescence agent claim 1 , a biocide claim 1 , a painkiller claim 1 , an anti-allergy agent and/or a plasticizer.5. The adhesive composition of wherein said hydrogel and/or water soluble polymer is polyethylene oxide).6. The adhesive composition of wherein said hydrogel is a natural polymer hydrogel derived from collagen claim 1 , hyaluronic acid claim 1 , fibrin claim 1 , alginate claim 1 , agarose and/or chitosan.7. The adhesive composition of wherein said photoinitiator is selected from the ...

Подробнее
Номер записи: 76
30-06-2016 дата публикации

LOW SWELL TISSUE ADHESIVE AND SEALANT FORMULATIONS

Номер: US20160184474A1
Автор: Dilucclo Robert C., Jenkins Lauri L.
Принадлежит: Actamax Surgical Materials, LLC

A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized dextran containing pendant aldehyde groups with a multi-arm polyethylene glycol amine is described. The hydrogel exhibits little to no swell upon exposure to physiological conditions. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a low swell hydrogel to inhibit complications, such as fibrosis, including scar formation or surgical adhesions. 1. A kit for forming a low swell hydrogel comprising:(a) a first aqueous solution or dispersion comprising one or more aldehyde-functionalized dextrans containing pendant aldehyde groups, said aldehyde-functionalized dextrans having a weight-average molecular weight of about 10,000 to about 20,000 Daltons and an equivalent weight per aldehyde group of about 226 to about 170; and wherein', '(i) the total concentration of the aldehyde-functionalized dextrans containing pendant aldehyde groups in the first aqueous solution or dispersion is about 5 wt % to about 20 wt % and the total concentration of the polyethylene glycols in the second aqueous solution or dispersion is about 10 wt % to about 18 wt %; or', '(ii) the total concentration of the aldehyde-functionalized dextrans containing pendant aldehyde groups in the first aqueous solution or dispersion is about 5 wt % to about 10 wt % and the total concentration of the polyethylene glycols in the second aqueous solution or dispersion is about 10 wt % to about 20 wt %., '(b) a second aqueous solution or dispersion comprising one or more polyethylene glycols having eight arms, substantially each arm of which is terminated with at least one primary amine group, wherein the polyethylene glycols have a number-average molecular weight of about 9,000 to about 11,000 Daltons;'}2. The kit of claim 1 , wherein the aldehyde-functionalized dextrans have an equivalent weight per aldehyde group of about 226 to about 185.3. The kit of claim 1 , wherein the total ...

Подробнее
Номер записи: 77
30-06-2016 дата публикации

METHODS AND COMPOSITIONS FOR DETECTING COAGULATION INHIBITORS

Номер: US20160187338A1
Автор: Chang Jen-Yea, Monroe Douglad
Принадлежит:

The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabigatran in the sample. 1. A method of identifying a coagulation inhibitor in a sample , comprising:a) contacting a first portion of the sample with a substrate and thrombin;b) contacting a second portion of the sample with a substrate and a2M-thrombin;c) contacting a third portion of the sample with a substrate and coagulation factor Xa;d) contacting a fourth portion of the sample with a substrate and a2M-Xa; ande) assaying for cleavage of the substrate in (a), (b), (c) and (d) above,wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample;cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample;cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, andcleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabigatran in the sample.2. The method of claim 1 , ...

Подробнее
Номер записи: 78
15-07-2021 дата публикации

Tissue-Adhesive Material

Номер: US20210213158A1
Автор: Denisov Konstantin Igorovitch, Schwab Leendert Willem, Tooren Martin Franke, Van Doormaal Theodorus Petrus Cornelis
Принадлежит:

The invention is directed to a tissue-adhesive polymer blend comprising a bioresorbable carrier polymer and a bioresorbable synthetic tissue-reactive polymer as well as to a tissue-adhesive device for sealing dura mater comprising said tissue-adhesive polymer blend. 117.-. (canceled)18. A tissue-adhesive device for sealing dura mater comprising a multilayered structure having at least a first layer and a second layer ,the first layer comprising a foam structure including a tissue-adhesive polymer blend comprising a bioresorbable carrier polymer and a bioresorbable synthetic tissue-reactive polymer, wherein the synthetic tissue-reactive polymer comprises a multi-arm polyethylene glycol functionalized with at least one tissue-reactive group that comprises an activated ester, andthe second layer comprising a sheet structure.19. The tissue-adhesive device of claim 18 , having an adhesive strength of more than 1 N.20. The tissue-adhesive device of claim 18 , having a burst-resistance of at least 8 mmHg.21. The tissue-adhesive device of claim 18 , having a burst-resistance of at least 15 mmHg.22. The tissue-adhesive device of claim 18 , having a burst-resistance of at least 30 mmHg.23. The tissue-adhesive device of claim 18 , having a burst-resistance of at least 45 mmHg.24. The tissue-adhesive device of claim 18 , wherein the carrier polymer is a synthetic carrier polymer and comprises one or more of a polyester claim 18 , polyether claim 18 , polyhydroxyacid claim 18 , polylactone claim 18 , polyetherester claim 18 , polycarbonate claim 18 , polydioxane claim 18 , polyanhydride claim 18 , polyurethane claim 18 , polyester(ether)urethane claim 18 , polyurethane urea claim 18 , polyamide claim 18 , polyesteramide claim 18 , poly-orthoester claim 18 , polyaminoacid claim 18 , polyphosphonate claim 18 , polyphosphazene.25. The tissue-adhesive device of claim 24 , wherein the synthetic carrier polymer comprises a poly(DL-lactide-co-ε-caprolactone) copolymer obtainable by the ...

Подробнее
Номер записи: 79
18-09-2014 дата публикации

INJECTABLE HYDROGELS

Номер: US20140277112A1
Автор: Borg Niklas, KÄLLROT Martina, Mellin Lisa
Принадлежит: ST. JUDE MEDICAL SYSTEMS AB

Described herein are methods of forming hydrogels comprising combining (a) a water-soluble polymer comprising thiol groups, and (b) a water-soluble metal salt in an aqueous solution. The hydrogels form rapidly. Hydrogels and related methods, uses, and products also are described. 1. A method for producing a hydrogel comprising combining(a) a water-soluble polymer comprising thiol groups, and(b) a water-soluble metal saltin an aqueous solution, thereby forming a hydrogel.2. The method of claim 1 , wherein the metal salt is a gold salt.3. The method of claim 2 , wherein the gold salt is selected from the group consisting of gold chloride claim 2 , potassium tetrachloroaurate claim 2 , potassium tetrabromoaurate claim 2 , potassium tetraiodoaurate claim 2 , sodium tetrachloroaurate claim 2 , sodium tetrabromoaurate claim 2 , sodium tetraiodoaurate claim 2 , sodium thiosulfatoaurate claim 2 , potassium gold cyanide (KAu(CN)) claim 2 , and combinations of one or more thereof.4. The method of claim 2 , wherein the gold salt is AuCl.5. The method of claim 1 , wherein the water-soluble polymer comprises a polymer backbone and claim 1 , optionally claim 1 , one or more branches and substituents.6. The method of claim 5 , wherein one or more of the backbone claim 5 , branches claim 5 , or substituents comprise a thiol group.7. The method of claim 6 , wherein a thiol group is attached at an end-cap position on one or more of the backbone claim 6 , branches claim 6 , or substituents.8. The method of claim 1 , wherein the molar ratio of thiol groups to metal atoms is from about 1000:1 to about 1:1.9. The method of claim 1 , wherein the method comprises combining (a) an aqueous solution comprising from about 1 to 20% by weight of the water-soluble polymer comprising thiol groups claim 1 , and (b) an aqueous solution comprising from about 0.05 to 20% by weight of the water-soluble metal salt.10. The method of claim 1 , wherein the water-soluble polymer comprises a polymer selected ...

Подробнее
Номер записи: 80
06-07-2017 дата публикации

PEPTIDE HYDROGEL PROPERTIES AND ITS APPLICATIONS

Номер: US20170189334A1
Автор: Carter Tiffany L., Huang Hongzhou, Sun Xiuzhi S.
Принадлежит:

Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage. 1. A hemostatic agent useful for promoting blood clotting and/or reducing hemorrhaging , said hemostatic agent comprising a peptide , wherein said peptide is amphiphilic and comprises a terminal hydrophobic region , a central turning region , and a terminal hydrophilic region.2. The hemostatic agent of claim 1 , wherein said peptide is in a solution comprising said peptide dispersed claim 1 , dissolved claim 1 , or suspended in a solvent system.3. The hemostatic agent of claim 1 , wherein said hydrophilic region is derived from a β-spiral motif of spider flagelliform silk protein claim 1 , and said hydrophobic and turning regions are derived from the third trans-membrane segment of subunit IV in the dihydropyridine sensitive human muscle L-type calcium channel.4. The hemostatic agent of claim 1 , further comprising albumin and/or calcium.5. The hemostatic agent of claim 1 , wherein said hydrophobic region consists of 2-15 amino acid residues selected from the group consisting of F claim 1 , L claim 1 , I claim 1 , V claim 1 , A claim 1 , H claim 1 , D claim 1 , P claim 1 , and G claim 1 , wherein at least one amino acid residue is I.6. The hemostatic agent of claim 1 , wherein said hydrophilic region consists of 5-20 amino acid residues claim 1 , wherein at least at least one amino acid residue is G claim 1 , at least one ...

Подробнее
Номер записи: 81
23-07-2015 дата публикации

METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION

Номер: US20150202265A1
Автор: Birr Elli, Haikola Merja, Hietala Oili, Jalovaara Pekka, Lumme Harri, Närhi Juha-Matti, Sandström Bo Kenneth, Tölli Hanna, Viitanen Mikko
Принадлежит: BBS-Bioactive Bone Substitutes OY

The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation. 1. A method of making a bone protein preparation comprising:a) demineralizing a bone and extracting the bone matrix with guanidine hydrochloride solvent to obtain a bone protein extract, b) filtering the extract with a microfilter with cut-off size in the range of 0.1-10 μm (nominal micron rating) sufficient for removing big particles and non-proteinous material but enabling proteins to pass,c) filtering the flow-through with a cassette ultrafilter having the cut-off size about 5-10 kDa to recover the bone protein preparation, andd) incorporating the bone preparation in a polyethylene glycol/glycerol (PEG-GLY) matrix.221-. (canceled)22. The method of claim 1 , wherein the cut-off size the microfilter of step b) is about 0.1-0.22 μm or about 1000 kDa.23. The method of claim 1 , further comprising dialyzing the bone protein preparation.24. The method of claim 1 , wherein the bone is a mammalian bone.25. The method of claim 24 , wherein the bone is an antler bone or a long bone.26. A bone protein preparation comprising Matrix Gla protein claim 24 , SPP-24 (secreted phosphoprotein) claim 24 , BMP-2 claim 24 , BMP-7 and TGF-beta 1 claim 24 , wherein said bone preparation is incorporated in a polyethylene glycol/glycerol (PEG-GLY) matrix.27. The bone protein preparation of claim 26 , wherein the bone preparation further comprises at least one of the following: biglycan claim 26 , thrombin claim 26 , lamin A/C claim 26 , vimentin claim 26 , chondroadherin claim 26 , 22K extracellular matrix protein claim 26 , lysyl oxidase claim 26 , osteonectin claim 26 , collagen or dermatopontin.28. The bone protein preparation of claim 26 , ...

Подробнее
Номер записи: 82
25-09-2014 дата публикации

FIBRIN SEALANT (FIBRINGLURAAS) CONSISTING OF A KIT OF LYOPHILIZED OR FROZEN HIGH CONCENTRATE FRIBINOGEN

Номер: US20140287044A1
Автор: Hoang Kieu
Принадлежит: Rare Antibody Antigen Supply, Inc.

The application is directed to a fibrin sealant (FIBRINGLURAAS®) consisting of a kit of lyophilized or frozen high concentrate fribinogen in which 5% a1at will be added into the final bulk and or 5% a1at as a diluent for high concentrate fibrinogen and new found proteins kh30, kh31, kh32, kh44, kh46, kh47, and kh52 in which the kh good healthy cells are present, either non-heated or heating to at least 1° C. and above, preferably at least 101° C., and lyophilized or frozen thrombin used to compound glue membrane, the diameter of which is less than 10 micrometers the actual size of the glue membrane of the fibrin sealant (FIBRINGLURAAS®) is from 0.6 μm, to 101° C. heating 0.005 micrometers and its topical applications for all solid tumor cancer 1. A method of purifying fibrinogen from plasma Fraction I or from plasma cryoprecipate comprising:a) collecting plasma cryopaste or Fraction I from human plasma;b) dissolving the Fraction I or cryopaste acquired in step a) in a pretreatment buffer, and conducting SID virus inactivation for enveloped virus;c) loading the treated solution from step b) to a canion chromatography;d) using cold ethanol precipitation to purify fibrinogen from the flow through in step c);e) loading elution buffer I to obtain factor VIII;f) dissolving a paste generated in step d) by using Buffer II for final formulation; andg) dialyzing and adding a stabilizer in the bulk acquired in step f).2. The method of claim 1 , wherein the Fraction I and cryopaste obtained by Cohn ethanol fractionation method.3. The method of claim 1 , wherein the pretreatment buffer includes Tris-HCl claim 1 , NaCl-citrate claim 1 , sucrose claim 1 , and NaCl.4. The method of claim 1 , further comprising enriching and preserving high concentrated fibrinogen with fibrinolysis A1AT during purification of the high concentrated fibrinogen.5. The method of further comprising claim 1 , improving the stability of a fibrin glue membrane by adding A1AT.6. The method of claim 5 , ...

Подробнее
Номер записи: 83
20-07-2017 дата публикации

Method for the manufacturing of di-chain proteins for use in humans

Номер: US20170204391A1
Автор: Annett Eylenstein, Kerstin Hoelscher, Swen Grein
Принадлежит: Merz Pharma GmbH and Co KGaA

This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins.

Подробнее
Номер записи: 84
05-08-2021 дата публикации

IMAGEABLE POLYMERS

Номер: US20210236660A1
Автор: Ashrafi Koorosh, DREHER Matthew R., HOHN Stephane, LEWIS Andrew Lennard, TANG Yiqing, Willis Sean Leo
Принадлежит:

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system. 137-. (canceled)38. A hydrogel comprising a cross-linked polymer network comprising a polymer having 1 ,2-diol or 1 ,3-diol groups and a radiopaque species covalently bound to the polymer through a cyclic acetal group , the radiopaque species comprising one or more covalently bound radiopaque halogens.39. A hydrogel according to wherein the radiopaque species comprises an iodinated aromatic group.40. A hydrogel according to wherein the radiopaque species comprises a brominated aromatic group.41. A hydrogel according to wherein the hydrogel comprises polyvinyl alcohol (PVA) in which the PVA comprises pendent groups formed from the acetalisation of PVA with N-acryloyl-aminoacetaldehyde dimethylacetal and which is cross-linked with 2-acrylamido-2-methylpropanesulfonic acid (PVA-AMPS).42. A hydrogel according to wherein the one or more covalently bound radiopaque halogens comprise bromine.43. A hydrogel according to wherein the one or more covalently bound radiopaque halogens comprise iodine.44. A hydrogel according to wherein the radiopaque species comprises an iodinated phenyl group.45. A hydrogel according to wherein the hydrogel comprises greater than 10% iodine by dry weight.46. A hydrogel according to wherein the hydrogel is in the form of microparticles or microspheres.47. A hydrogel according to wherein the hydrogel is in the form of microspheres with a mean diameter size range of from 10 to 2000 μm.48. A hydrogel according to in the form of microspheres or microparticles having a mean radiopacity of 500HU or greater.49. A hydrogel according to wherein the hydrogel has a net charge at physiological pH.52. A composition ...

Подробнее
Номер записи: 85
25-06-2020 дата публикации

MULTIBLOCK COPOLYPEPTIDES OF ELASTIN-BASED POLYPEPTIDES AND MUSSEL FOOT PROTEINS WITH STIMULI-RESPONSIVENESS AND SURFACE-ADHESIVE, METHODS OF PREPARING THEREOF AND USE THEREOF

Номер: US20200199199A1
Автор: Lee Jae Hee, Lee Jae Sang, LIM Dong Woo
Принадлежит: Industry-University Cooperation Foundation Hanyang University ERICA Campus

The present disclosure relates to a multiblock copolypeptide having stimulus responsivity and surface adhesiveness. The multiblock copolypeptide of the present disclosure, which is composed of an elastin-based polypeptide and a mussel foot protein, can form self-assembled core-shell structures and hydrogels exhibiting reversible change in response to temperature stimulation and can be used usefully for biomedical applications due to remarkably superior surface adhesiveness. 1. A multiblock copolypeptide comprising:an elastin-based polypeptide (EBP); anda mussel foot protein (MFP).2. The multiblock copolypeptide according to claim 1 , wherein the multiblock copolypeptide is composed of an arrangement selected from a group consisting of (EBP)(MFP) claim 1 , (EBP)(MFP)(EBP)and (MFP)(EBP)(MFP) claim 1 , wherein the n claim 1 , which is an integer 1 or greater claim 1 , is the number of EBP or MFP repeat unit.3. The multiblock copolypeptide according to claim 1 , wherein the elastin-based polypeptide (EBP) is composed of an amino acid sequence selected from a group consisting of a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block claim 1 , a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block and an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block claim 1 , wherein the X is an amino acid excluding proline.4. The multiblock copolypeptide according to claim 3 , wherein the X of the [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block comprises:A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1;K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1;D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1;E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1;G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2;K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2;D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2;K (Lys) and F (Phe) at a ratio of 3:3;D (Asp) and F (Phe) at a ratio of 3:3;H (His), A (Ala) and I (Ile) at a ratio of 3:2:1;H (His) and G (Gly) at a ratio of 5:1; orG (Gly), C (Cys) and F (Phe) at a ratio of 1:3:2.5. The ...

Подробнее
Номер записи: 86
04-08-2016 дата публикации

SYSTEM FOR SUTURELESS CLOSURE OF SCLERAL PERFORATIONS AND OTHER OCULAR TISSUE DISCONTINUITIES

Номер: US20160220725A1
Автор: BAYAT Niki, FALABELLA Paulo, Humayun Mark S., III John J., Thompson Mark E., Whalen, Zhang Yi
Принадлежит: UNIVERSITY OF SOUTHERN CALIFORNIA

The present disclosure describes, among other things, a thermo-responsive hydrogel comprising a PNIPAM copolymer having adhesive properties that are temperature dependent, as well as a device for administering the hydrogel, and methods for making and using the foregoing. 1. A temperature-responsive hydrogel comprising a poly(N-isopropylacrylamide) copolymer at a concentration of about 10 weight percent to about 60 weight percent in water , wherein the copolymer (i) is a copolymer of poly(N-isopropylacrylamide) and a second polymer that is either N-tert-butylacrylamide or butylacrylate , (ii) has a weight percent ratio of poly(N-isopropylacrylamide) to the second polymer of about 99:1 to about 50:50 , and (iii) has a number average molecular weight of about 5 ,000 to about 5 ,000 ,000 daltons.2. The hydrogel of claim 1 , wherein the poly(N-isopropylacrylamide) copolymer is a poly(N-isopropylacrylamide):N-tert-butylacrylamide copolymer.3. The hydrogel of claim 1 , wherein the poly(N-isopropylacrylamide) copolymer is a poly(N-isopropylacrylamide):butylacrylate copolymer.4. The hydrogel of claim 1 , wherein the weight percent ratio of poly(N-isopropylacrylamide) to the second polymer is selected from 99:1 claim 1 , 95:5 claim 1 , 90:10 claim 1 , 85:15 claim 1 , 80:20 claim 1 , 75:25 claim 1 , 70:30 claim 1 , 65:35 claim 1 , 60:40 claim 1 , 55:45 and 50:50.5. The hydrogel of claim 1 , wherein the weight percent ratio of poly(N-isopropylacrylamide) to the second polymer is in a range of about 95:5 to about 70:30.6. The hydrogel of claim 1 , wherein the copolymer has a number average molecular weight of about 10 claim 1 ,000 to about 3 claim 1 ,000 claim 1 ,000 daltons.7. The hydrogel of claim 1 , wherein the copolymer has a number average molecular weight of about 20 claim 1 ,000 to about 2 claim 1 ,000 claim 1 ,000 daltons.8. The hydrogel of claim 1 , having a copolymer concentration in water selected from the group consisting of about 10 weight percent claim 1 , 15 ...

Подробнее
Номер записи: 87
03-08-2017 дата публикации

BIOLOGICAL TISSUE ADHESIVE COMPOSITION AND METHOD OF PREPARATION THEREOF

Номер: US20170216485A1
Автор: Fan Changjiang, Wang Dongan
Принадлежит:

A biological tissue adhesive composition is provided. The biological tissue adhesive composition comprises one or more macromolecules grafted with at least one catechol moiety and comprising at least one cross-linkable functional group, a first cross-linker for cross-linking the at least one catechol moiety, wherein the first cross-linker comprises or consists or 10 a multivalent metal ion, and a second cross-linker for covalently cross-linking the at least one cross-linkable functional group, wherein the one or more macromolecules are cross-linked by (a) complex formation between the at least one catechol moiety and the multivalent metal ion, and (b) covalent bonding of the at least one cross-linkable functional group with the second cross-linker. Fabrication method and working principle of a biological tissue adhesive composition are also provided. 1. A biological tissue adhesive composition , comprising(i) a gluing macromer comprising one or more macromolecules grafted with at least one catechol moiety and comprising at least one cross-linkable functional group;(ii) a first cross-linker for cross-linking the at least one catechol moiety, wherein the first cross-linker comprises or consists of a multivalent metal ion; and(iii) a second cross-linker for covalently cross-linking the at least one cross-linkable functional group,wherein the one or more macromolecules are cross-linked by (a) complex formation between the at least one catechol moiety and the multivalent metal ion, and (b) covalent bonding of the at least one cross-linkable functional group with the second cross-linker.2. The biological tissue adhesive composition according to claim 1 , wherein the one or more macromolecules does not contain an aldehyde group and/or a cyan group.3. The biological tissue adhesive composition according to or claim 1 , wherein the one or more macromolecules is selected from the group consisting of an amino group functionalized polysaccharide claim 1 , a polyamino acid claim ...

Подробнее
Номер записи: 88
16-10-2014 дата публикации

INTERVERTEBRAL DISC REPAIR, METHODS AND DEVICES THEREFOR

Номер: US20140308251A1
Автор: Adkisson H. Davis, Seyedin Mitchell S.
Принадлежит: ISTO TECHNOLOGIES, INC.

The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc through an aperture or incision. If the aperture or incision is closed with a suture or a glue after introduction of the chondrocytes, the closure can withstand over 400 N of compression force. 1. A method of implanting viable chondrocytes in a degenerative intervertebral disc in a subject , the method comprising:a) injecting through an opening in the annulus of the degenerative intervertebral disc, into the nucleus pulposus of the disc, a composition comprising: (i) a suspension of a population of viable articular cartilage chondrocytes; (ii) thrombin; and (iii) fibrin;b) forming a closure of the opening following injection of the cell suspension composition.2. A method according to claim 1 , wherein the composition comprises a first mixture comprising the viable population of viable articular cartilage chondrocytes suspended in a thrombin solution claim 1 , and a second mixture comprising fibrinogen claim 1 , the method further comprising combining the first mixture and the second mixture to form the composition immediately before or during injection.3. A method according to claim 2 , wherein the first mixture is contained in a first barrel of a double-barrel syringe claim 2 , and the second mixture contained in a second barrel of the double-barrel syringe claim 2 , and wherein combining the first mixture and the second mixture comprises combining the first mixture and the second mixture while extruding the mixtures simultaneously from the first and ...

Подробнее
Номер записи: 89
02-07-2020 дата публикации

SYSTEMS AND METHODS FOR PREPARING A THROMBIN SERUM

Номер: US20200206325A1
Автор: Bare Christopher, Harrison Robert, Nabors Abigail, TUCKER Melissa
Принадлежит: Arthrex, Inc.

A system for preparing a thrombin serum that can include a containment device, a cage received within the containment device, a cap attachable to the containment device, an inlet port configured to introduce a non-anti-coagulated autologous blood fluid into the containment device, and an outlet port. An activator, such as glass beads, can be present within the containment device. 1. A method for preparing a thrombin serum , comprising: (a) a longitudinal axis;', '(b) a cage received within said containment device, the cage having a wall or walls that extend along a longitudinal axis into the containment device, wherein the cage wall or walls include a plurality of openings;', '(c) a cap attached to said containment device;', '(d) an inlet port configured to introduce the non-anti-coagulated autologous blood fluid into said containment device, wherein the inlet port is located radially outwardly of the cage relative to the longitudinal axis, such that a fluid is delivered to the containment device between an inner wall of the containment device and an outer wall of the cage; and', '(e) an outlet port configured to remove a thrombin serum from said containment device;, '(i) Incubating a first amount of a non-anticoagulated autologous blood fluid in a containment device, wherein the containment device comprises(ii) extracting a thrombin serum from the containment device.2. The method of claim 1 , further comprising adding the thrombin serum to a second autologous blood fluid to produce a clotted product.3. The method of claim 1 , comprising claim 1 , prior to extracting the thrombin serum: adding a second amount of the non-anticoagulated autologous blood fluid to the containment device; shaking the containment device; and incubating the containment device a second time.4. The method of claim 1 , further comprising shaking the containment device a second time claim 1 , and incubating the containment device a third time.5. The method of claim 1 , further comprising ...

Подробнее
Номер записи: 90
11-07-2019 дата публикации

WOUND CLOSURE COMPOSITIONS AND METHOD

Номер: US20190209733A1
Автор: Russo Joseph D.
Принадлежит: Rousseau Research, Inc.

A medical adhesive that bonds well to human tissue while curing in a fast, controllable manner. In a preferred form, the medical adhesive includes an oligomer, a hydrogel and/or water soluble polymer and a photoinitiator. Preferred oligomers include epoxides, urethanes, polyethers, polyester or a combination thereof. Hydrogels and water soluble polymers aid adhesion to moist surfaces, such as skin tissue, because they are hydrophilic and biodegradable. Preferred hydrogels include polymer hydrogels (PHGs). Suitable water soluble polymers include polyethylene oxide) (PEO) and poly-2-oxazoline. The photoinitiator is used to obtain fast, controllable curing of the adhesive compound. Curing takes place on demand when ultraviolet (UV) light is applied to the medical adhesive. To increase adhesion as well as to control flexibility and toughness, the medical adhesive may also include one or more monomers. Suitable monomers include acrylates and vinyls. 112-. (canceled)13. A method of applying and curing an adhesive composition to animal tissue comprising the steps of:providing a liquid adhesive composition comprising an oligomer, a N-vinylpyrrolidone monomer, a water soluble polymer and a photoinitiator sensitive to ultraviolet light;applying said adhesive composition to animal tissue; and,exposing said adhesive composition on said tissue to ultraviolet light to cure said adhesive composition in situ.14. The method of wherein said animal tissue is human skin and said adhesive is applied to seal or bind together a cut or Wound in said skin.15. The method of wherein said tissue is human skin and said adhesive is applied to protect said skin from damage.16. The method of wherein said oligomer is selected from the group consisting of epoxides claim 13 , urethanes claim 13 , polyethers claim 13 , polyesters or a combination thereof.17. The method of wherein said adhesive composition further comprises a chromophore claim 13 , a fluorescence agent claim 13 , a biocide claim 13 , a ...

Подробнее
Номер записи: 91
11-08-2016 дата публикации

Oily Compositions

Номер: US20160228597A1
Автор: DREHER Matthew R.
Принадлежит: BIOCOMPATIBLES UK LTD

The invention provides pharmaceutical compositions comprising embolic particles, that optionally comprise pharmaceutical actives, in oil or emulsion formulations that are useful in therapeutic embolisation procedures, particularly for the treatment of vascularised neoplasias, such as liver carcinomas. 1. A pharmaceutical composition comprising a halogenated oil and one or more embolic particles in the form of an emulsion comprising an aqueous phase and an oily phase.2. A pharmaceutical composition according to wherein the halogenated oil is Lipiodol®.3. A pharmaceutical composition according to or wherein the embolic particles comprises a pharmaceutical active.4. A pharmaceutical composition according to to which comprises a pharmaceutical active in the oil phase and/or the aqueous phase.5. A pharmaceutical composition according to which comprises a hydrophobic pharmaceutical active dissolved in the oil phase.6. A pharmaceutical composition according to any preceding claim which is in the form of a water in oil emulsion.7. A pharmaceutical composition according to any of to in which the ratio of Lipiodol to aqueous phase is ≧1 (Lipiodol):1 (aqueous phase) (V/V)8. A pharmaceutical composition according to any preceding claim in which the specific gravity of the aqueous phase is between 1.15 and 1.35.9. A pharmaceutical composition according to any preceding claim wherein the specific gravity of the particle is between 1.0 and 1.5.10. A pharmaceutical composition according to any preceding claim in which the embolic particles are hydrophilic.11. A pharmaceutical composition according to any preceding claim in which the embolic particles comprise a hydrogel.12. A pharmaceutical composition according to any preceding claim in which the embolic particles comprise a polymer selected from PVA claim 4 , cross linked PVA claim 4 , PVA-AMPS and PVA co-sodium acrylate.13. A pharmaceutical composition according to any preceding claim wherein the ratio of Lipiodol to embolic ...

Подробнее
Номер записи: 92
09-07-2020 дата публикации

POUCHED UNIT AND METHOD OF USING SAID POUCHED UNIT

Номер: US20200216243A1
Автор: BOOD Arie
Принадлежит:

A pouched unit comprising a dose of a substance which is enveloped by a main part of a pouch made from a water soluble material, wherein the pouch comprises a secondary part made from the water soluble material, the secondary part is attached to the main part via a weaker area of the water soluble material, which weaker area is configured to allow manual separation of the secondary part from the main part, and the substance comprises a food material. 1. A pouched unit comprising a dose of a substance which is enveloped by a main part of a pouch made from a water soluble material , wherein;the pouch comprises a secondary part made from the water soluble material,the secondary part is attached to the main part via a weaker area of the water soluble material, which weaker area is configured to allow manual separation of the secondary part from the main part, andthe substance comprises a food material.2. The pouched unit according to claim 1 , wherein the pouch has a lower tensile strength at the weaker area when compared with the main part and the secondary part.3. The pouched unit according to claim 1 , wherein the secondary part extends away from the main part.4. The pouched unit according to claim 1 , wherein a message is provided on the secondary part.5. The pouched unit according to claim 4 , wherein the message comprises a text or a symbol.67.-. (canceled)8. The pouched unit according to claim 1 , wherein the secondary part comprises a flavouring for the food material.9. The pouched unit according to claim 8 , wherein the flavouring comprises a container formed by the water soluble material of the secondary part and the container holds a flavouring fluid or a flavouring powder.10. The pouched unit according to claim 9 , wherein the flavouring is a different material than the food material of the dose of substance.1112.-. (canceled)13. The pouched unit according to claim 1 , wherein the pouch is only formed by the water soluble material.14. The pouched unit ...

Подробнее
Номер записи: 93
27-08-2015 дата публикации

PLASMA-SUPPLEMENTED FORMULATION

Номер: US20150238529A1
Автор: AUERBACH-NEVO Tamar, Belyaev Oleg, Grimberg Elena, Meidler Roberto, Nur Israel, TIBERMAN Yonit
Принадлежит:

Provided herein is a plasma-supplemented fibrinogen and/or fibrin formulation, method for the preparation and use thereof. 1. A method of preparing a fibrinogen formulation comprising a step of:mixing a concentrated fibrinogen preparation and a plasma source.2. The method of claim 1 , wherein the concentrated fibrinogen preparation is derived from blood or a blood fraction.3. The method of claim 1 , wherein the fibrinogen concentration in the concentrated fibrinogen preparation is in the range of about 10 mg/ml to 200 mg/ml.4. The method of claim 1 , wherein the fibrinogen concentration in the concentrated fibrinogen preparation is in the range of about 10 mg/ml to 150 mg/ml.5. The method of claim 1 , wherein the concentrated fibrinogen preparation is a cryoprecipitate.6. The method of claim 5 , wherein the cryoprecipitate is a Factor VIII-depleted cryoprecipitate.7. The method of claim 1 , wherein the concentrated fibrinogen preparation and the plasma are mixed in a ratio of about 1:1.8. A plasma-supplemented fibrinogen formulation.9. A fibrinogen formulation obtainable according to the method of .10. The fibrinogen formulation of or claim 1 , for use as a component of a fibrin sealant.11. A sealant formulation comprising a plasma-supplemented fibrinogen.12. A method for preparing a sealant at a surface comprising applying to the surface a plasma-supplemented fibrinogen component and a thrombin component.13. A sealant formulation comprising fibrin monomers prepared from a plasma-supplemented fibrinogen.14. A container comprising the formulation of any one of claim 1 , claim 1 , or .15. A kit comprising the container of claim 14 , and optionally instructions for use.16. A method of sealing claim 14 , healing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a formulation of any one of claim 14 , claim 14 , or .17. The method of comprising applying to the subject an effective amount of a formulation ...

Подробнее
Номер записи: 94
27-08-2015 дата публикации

VISCOUS HAEMOSTATIC COMPOSITIONS AND METHOD OF TREATMENT

Номер: US20150238652A1
Автор: Eutick Malvin
Принадлежит: EUPHARMA PTY LTD

A method of promoting haemostasis in a patient is provided by the administration, to the site of blood loss, of a viscous thixotropic haemostatic composition comprising an ionic precipitating agent, a fatty alcohol, an alcohol phosphate diester and one of an alkoxyether phosphate or a monoester phosphate of an alkoxylated fatty alcohol. 1. A method of promoting haemostasis in a patient in need thereof including the step of administering to the site of blood loss a viscous thixotropic haemostatic gel composition comprising an ionic precipitating agent , a fatty alcohol , an alcohol phosphate diester and one of an alkoxyether phosphate or a monoester phosphate of an alkoxylated fatty alcohol.2. (canceled)3. The method of wherein the ionic precipitating agent comprises a cation selected from the group consisting of iron claim 1 , silver claim 1 , aluminium claim 1 , calcium claim 1 , magnesium claim 1 , manganese and ammonium cations.4. The method of wherein the ionic precipitating agent comprises a salt of a metal wherein the salt is selected from the group consisting of chloride claim 1 , nitrate claim 1 , sulphate and acetate salts.5. The method of wherein the ionic precipitating agent is selected from the group consisting of ferric chloride claim 4 , an iron sulphate claim 4 , inclusive of ferric subsulphate claim 4 , silver nitrate claim 4 , silver chloride claim 4 , aluminium chloride hexahydrate claim 4 , aluminium sulphate and aluminium acetate.6. The method of wherein the ionic precipitating agent is present in the composition as Monsel's solution.7. The method of wherein the fatty alcohol has between 10 to 22 carbon atoms.8. The method of wherein the fatty alcohol is selected from the group consisting of myristyl alcohol claim 7 , pentadecyl alcohol claim 7 , cetyl alcohol claim 7 , heptadecyl alcohol claim 7 , stearyl alcohol claim 7 , nonadecyl alcohol and arachidyl alcohol.9. The method of wherein the fatty alcohol is a mix of cetyl and stearyl alcohols.10 ...

Подробнее
Номер записи: 95
17-08-2017 дата публикации

ELASTIC BIOPOLYMER AND USE AS A TISSUE ADHESIVE

Номер: US20170232138A1
Автор: Annabi Nasim, ASSMANN Alexander, Khademhosseini Ali
Принадлежит: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics. 1. A tissue adhesive comprising a light activated methacryloyl-substituted gelatin , a photoinitiator and a pharmaceutically acceptable carrier.2. The tissue adhesive of claim 1 , wherein the methacryloyl-substituted gelatin has a degree of methacryloyl substitution between 50% and 90%.34.-. (canceled)5. The tissue adhesive of claim 1 , wherein the methacryloyl-substituted gelatin is present at a concentration between 10% and 40% (w/v).68.-. (canceled)9. The tissue adhesive of claim 1 , wherein the photoinitiator is selected from the group consisting of: 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one claim 1 , azobisisobutyronitrile claim 1 , benzoyl peroxide claim 1 , di-tert-butyl peroxide claim 1 , 2 claim 1 ,2-dimethoxy-2-phenylacetophenone claim 1 , Eosin Y claim 1 , and any combination thereof.10. (canceled)11. The tissue adhesive of claim 1 , further comprising:(i) a hemostatic agent selected from the group consisting of ...

Подробнее
Номер записи: 96
25-07-2019 дата публикации

CELL-SEEDED POROUS LUNG HYDROGEL SEALANT

Номер: US20190224364A1
Автор: "ONeill John", Bacchetta Matthew, Guenthart Brandon, Kim Jinho, Vunjak-Novakovic Gordana
Принадлежит:

Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak. 1. A biosealant composition comprising an extracellular matrix hydrogel and a thermogel;wherein the extracellular matrix hydrogel comprises a first extracellular matrix protein, an unbranched polysaccharide, and an elastic protein; andwherein the thermogel comprises a gelatinous material and a cross-linking enzyme in an amount sufficient to result in gelation of the thermogel at a temperature from about 35° C. to 37° C.2. The biosealant of claim 1 , wherein the first extracellular matrix protein is collagen claim 1 , wherein the elastic protein is elastin claim 1 , and wherein the unbranched polysaccharide is sulfated glycosaminoglycan.3. The biosealant of claim 1 , wherein the cross-linking enzyme is transglutaminase.4. The biosealant of claim 1 , wherein the extracellular matrix hydrogel also comprises additional therapeutics including cells claim 1 , microsomes claim 1 , peptides claim 1 , or drugs.5. The biosealant of claim 1 , wherein the cross-linking enzyme is present in an amount from about 0.5 units/mL to 5 units/mL.6. The biosealant of claim 1 , wherein the gelatinous material is gelatin.7. The biosealant of claim 1 , wherein the thermogel comprises pores of diameter of about 0.025 mm to 90 mm.8. The biosealant of claim 1 , wherein the biosealant composition does not contain fibrin.9. The biosealant of claim 1 , wherein the first extracellular matrix protein is present in an amount from about 25% by weight to about 75% by weight of the total weight of the first extracellular matrix protein claim 1 , unbranched polysaccharide claim 1 , and elastic protein of the extracellular matrix hydrogel.10. The biosealant of claim 1 , wherein the unbranched polysaccharide is present in an amount from about 0.5% by weight to about 15% by weight of the total weight of the first extracellular matrix protein claim 1 , ...

Подробнее
Номер записи: 97
25-08-2016 дата публикации

SURGICAL ADHESIVE AND USES THEREFORE

Номер: US20160243272A1
Автор: MILBOCKER Michael T., POPPAS Dix P.
Принадлежит: Promethean Surgical Devices, LLC

The present invention provides a liquid polymer composition which can be implanted into a living mammal and which forms a solid hydrogel by in situ polymerization upon contact with body fluid and tissue. The composition also can be used as a coating on a medical device, or for the formation of a medical device. Formation of a solid implant or coating involves crosslinking of the adhesive with itself and with surrounding tissue. The liquid implant, by itself or in conjunction with various prostheses, can be used for many purposed, including fixation of the urethra for providing treatment for incontinence, and repair of herniations in the abdominal cavity, including rectocele, cystocele, enterocele, and inguinal hernia. The adhesive may be used to establish adhesion prevention during such repairs, in part by coating or being the material of a repair mesh. 1. (canceled)260-. (canceled)61. A method of repairing a tissue defect comprising:providing an adhesive composition including at least one species of isocyanate-capped polymeric polyether-polyol comprising a copolymer of oxyethylene with propylene oxide and triols, and at least one species of polyisocyanate with molecular weight below about 2000 D;applying the adhesive composition to a reinforcing material selected from the group consisting of a mesh and a flock to form a reinforced adhesive composition; andapplying the reinforced adhesive composition to the tissue defect to repair the defect.62. The method of claim 61 , wherein the step of applying the adhesive composition to a reinforcing material comprises applying the adhesive composition to a woven or non-woven mass or sheet of fibril claim 61 , or a dispersed fibrillar material.63. The method of claim 61 , wherein the isocyanate-capped polymeric polyether-polyol comprises a copolymer of about 70% or more claim 61 , on a molar basis oxyethylene.64. The method of claim 61 , further comprising curing the reinforced adhesive composition.65. A method of repairing a ...

Подробнее
Номер записи: 98
01-08-2019 дата публикации

COMPOSITIONS OF HUMAN PROTHROMBIN AND ACTIVATED FACTOR X FOR IMPROVING HEMOSTASIS IN THE TREATMENT OF BLEEDING DISORDERS

Номер: US20190231855A1
Автор: Dockal Michael, Knappe Sabine, Scheiflinger Friedrich, Till Susanne, Turecek Peter Leopold
Принадлежит:

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein. 112.-. (canceled)13. A method of treating a bleeding disorder comprising administering a composition including prothrombin (FII) and activated factor X (FXa) wherein the molar ratio of FXa to FII is more than 1:20 ,000.14. The method of claim 13 , wherein the molar ratio of FXa to FII is more than 1:10 claim 13 ,000.15. The method of claim 13 , wherein the concentration of FII in the composition is about 105-700 nM.16. The method of claim 13 , wherein the FII and FXa is plasma derived or recombinant.17. The method of claim 13 , wherein the concentration of FII is about 0.44 mg/kg and the concentration of FXa is about 826 ng/kg.18. The method of claim 13 , wherein the concentration of FII is about 0.2 mg/kg to about 1 mg/kg and the concentration of FXa is about 560 ng/kg to about 1100 ng/kg.19. The method of claim 13 , wherein the concentration of FII is about 4.4 mg/kg and the concentration of FXa is about 275 ng/kg.20. The method of claim 13 , wherein the concentration of FII is about 1.2 mg/kg to about 5 mg/kg and the concentration of FXa is about 200 ng/kg to about 540 ng/kg.21. The method of claim 13 , wherein the bleeding disorder is hemophilia A claim 13 , hemophilia B claim 13 , von Willebrand disease claim 13 , congenital hemophilia A with inhibitors or acquired hemophilia A with inhibitory auto antibodies to FVIII claim 13 , congenital hemophilia B with inhibitors or acquired hemophilia B with inhibitory auto antibodies to FIX claim 13 , blood loss from trauma claim 13 , FVII deficiency claim 13 , FV deficiency claim 13 , FX deficiency claim 13 , FXI deficiency claim 13 , FXIII deficiency claim 13 , ...

Подробнее
Номер записи: 99
13-11-2014 дата публикации

IN SITU CROSSLINKING HYDROGEL COMPRISING gamma-POLYGLUTAMIC ACID AND METHOD FOR PRODUCING THE SAME

Номер: US20140336276A1
Автор: Kim Hea-Kyung, KIM Sun-woo, Koh Young-Joo, YEO Guw-dong
Принадлежит:

Disclosed are a biodegradable, biocompatible hydrogel that can be used for sealants of suppressing the leakage of blood or air during surgical operation, tissue adhesives, anti-adhesive agents and drug delivery carriers, and a method for producing the same 2. The γ-polyglutamic acid derivative of claim 1 , wherein the linker is —HN—(R)a-O— (R is CH claim 1 , and a is an integer of 1 to 5).3. The γ-polyglutamic acid derivative of claim 2 , wherein the linker is derived from aminomethanol claim 2 , 1-amino-2-propanol claim 2 , 1-amino-3-propanol claim 2 , 1-amino-4-butanol claim 2 , 1-amino-5-pentanol claim 2 , or 2-aminoethanol.4. The γ-polyglutamic acid derivative of claim 1 , wherein —(CO)b-(R)c-CO— is —CHCHCHCH—CO— claim 1 , —CO—CHCHCH—CO— claim 1 , —CHCH—CO— claim 1 , —CO—CHCH—CO— claim 1 , or —CH—CO—.5. A method of preparing the γ-polyglutamic acid derivative of claim 1 , which comprisesa first step of reacting a γ-polyglutamic acid with a lower alkanolamine having 1 to 5 carbon atoms to form a γ-polyglutamic acid-alkanolamine;a second step of reacting the γ-polyglutamic acid-alkanolamine with an anhydride of an acid selected from the group consisting of glutaric acid and succinic acid, or 1-halo alkanoic acid selected from the group consisting of 1-halo valeric acid, 1-halo propionic acid and 1-halo methylcarbonic acid to form an alkanoic acid terminal; anda third step of reacting the thus formed carboxyl terminal with N-hydroxysuccinimide or N-hydroxysulfosuccinimide to form a γ-polyglutamic acid derivative of which at least some carboxyl groups are activated.6. The method of preparing the γ-polyglutamic acid derivative according to claim 5 , wherein in the first step claim 5 , the lower alkanolamine is reacted in a molar ratio of 0.1 to 2 with regard to a mole unit of the carboxyl groups of the γ-polyglutamic acid.7. The method of preparing the γ-polyglutamic acid derivative according to claim 5 , wherein in the second step claim 5 , the anhydride of an acid ...

Подробнее
Номер записи: 100